Detection of pathological protein aggregation
By employing extracellular vesicle samples enriched through size exclusion chromatography and methods like RT-QuIC, the detection of pathological alpha-synuclein provides a sensitive and reliable early diagnostic for protein misfolding neurodegenerative disorders.
Patent Information
- Application Number
- JP2023127705
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-03-06
- Filing Date
- 2023-08-04
- Publication Date
- 2024-11-21
- Estimated Expiration
- 2039-03-05
AI Technical Summary
Current diagnostic methods for early-stage protein misfolding neurodegenerative disorders like Parkinson's disease and Lewy body dementia lack sensitivity and reliability, relying heavily on neuropsychiatric evaluations that are often delayed and ineffective.
The use of extracellular vesicle samples from patients, enriched using size exclusion chromatography, to detect pathological alpha-synuclein through methods like RT-QuIC and PMCA, providing a more sensitive and reliable marker for disease presence and risk.
This approach allows for the early detection of protein misfolding disorders before clinical symptoms appear, offering a more sensitive and specific diagnostic tool for conditions such as Parkinson's disease and Lewy body dementia.
Smart Images

Figure 0007587880000001 
Figure 0007587880000002 
Figure 0007587880000003
Abstract
Description
[Technical field]
[0001] The present invention uses extracellular vesicle samples to detect protein misfolding in a subject. Neurodegenerative disorders, especially alpha-synucleinopathies (Parkinson's disease and Lewy bodies) The present invention provides a novel method for identifying, monitoring, or determining the risk of developing dementia (including type 2 dementia) in a patient with dementia. In addition, the presence of pathological prion-like proteins (or one or more cerami Corresponding methods of selecting and assaying for the presence of a particular marker (such as a marker species) are also provided. [Background technology]
[0002] Many neurodegenerative disorders are associated with protein misfolding, aggregation, and tissue accumulation. These disorders, referred to herein as "protein misfolding neurodegenerative disorders," Such disorders include Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, Creutzfeldt's disease, and ·Credit cardiomyopathy, Alzheimer's disease, tauopathy (Alzheimer's disease, frontotemporal lobar degeneration, Progressive supranuclear palsy, corticobasal degeneration, etc.), Huntington's disease, motor neuron disease , Dentatopallidorubrol uysian atrophy), spinocerebellar ataxia, and many others ( Salvadores et al., 2014 (Non-Patent Document 1)).
[0003] Identifying affected individuals in the early stages of the disease, before clinical symptoms appear, is generally problematic. The aim of this study is to identify risk factors for the development of protein misfolding neurodegenerative disorders. widely accepted, reliable, sensitive and Due to the lack of objective molecular diagnostic methods, the diagnosis of such diseases is therefore based on neurological and rely heavily on neuropsychiatric evaluation, which typically occurs late in the development of the disease. It just doesn't help with diagnosis.
[0004] One example is Parkinson's disease, a condition in which parts of the brain become gradually damaged over many years. The main symptoms of Parkinson's disease are involuntary shaking (tremors), movement in certain parts of the body, and Patients with Parkinson's disease may also experience depression and anxiety, problems with balance, and muscle stiffness. Symptoms include loss of smell (anosmia), sleep disorders (insomnia), and memory problems, among others. Patients may experience a variety of physical and psychological symptoms.
[0005] In addition, there are two types of dementia associated with Parkinson's disease: Parkinson's disease dementia and and Lewy body dementia. The motor symptoms of Parkinson's disease may be present for a short time before the onset of dementia. If present for at least one year, it is differentiated from Parkinson's disease dementia. Dementia is characterized by symptoms of dementia that precede or are similar to symptoms of Parkinson's disease. The diagnosis is made when Parkinson's disease occurs occasionally. negotiation of the environment They also tend to have greater difficulty in thinking. stomach.
[0006] Currently, the diagnosis is based on the patient's symptoms, medical history, and a thorough physical examination. Early stage Parkinson's disease is particularly difficult to diagnose because symptoms are usually mild. A complete clinical diagnosis is now established in a highly specialized clinical setting, and The diagnosis is based on neuropsychological and neuroradiological evaluation. Repeated consultations are required, which delays diagnosis and delays the initiation of treatment and support. There is currently no cure for Parkinson's disease, but there are many different treatments available to help manage the condition. There is treatment, therapy and support.
[0007] Parkinson's disease affects one in 500 people, which is the number of people with this condition in the UK. This means that there are an estimated 127,000 people with Parkinson's disease. Most people with Parkinson's disease live for 5-8 years. Symptoms begin to appear after the age of 0, but about one in 20 patients with this condition is under the age of 40. Men are slightly more likely to develop Parkinson's than women. According to a United Nations study, by 2050, 1.8 billion people will be over 60 years old, and 18, It has been reported that 000,000 potential new cases are predicted.
[0008] At least 500,000 people in the United States are thought to have Parkinson's disease, with Approximately 50,000 new cases are reported each year. Parkinson's disease costs the US $14.4 billion annually. Indirect costs (e.g., lost employment) have been conservatively estimated at $6.3 billion. These costs are estimated at $20,000 per person (or nearly $10,000 per person). It is predicted to double by 2040. In the UK, the cost is estimated at £400 million per year. The cost of Parkinson's disease is estimated at £3.3 billion from 2017. Research has shown that the cost of early diagnosis is This can be significantly reduced through improvements in planning, avoidance of future hospitalizations, and clinical management. It has been shown to be useful for improving
[0009] At the molecular level, alpha-synuclein aggregation is a cause of Parkinson's disease (PD), Lewy cell myopathy, and It plays a central role in the pathology of dementia morbidis (DLB) and multiple system atrophy (MSA). Alpha-synuclein is known to be involved in the transport of exosomes and other extracellular microorganisms. It is a 140 amino acid long protein that has been detected both inside and outside the vesicle (Loov (Reviewed in Non-Patent Document 2, 2016). Changes in lupus-synuclein levels (e.g., in cerebrospinal fluid (CSF) samples) Despite many studies showing a slight decrease in fasciol synuclein levels, The data are inconsistent, and the methods for measuring alpha-synuclein between laboratories vary. Standardization of the methodology currently available has proven difficult. The alpha present in the subject's biological sample (including the extracellular vesicle sample) is then detected. Total -synuclein does not appear to be a reliable biomarker of disease.
[0010] In the pathological state, alpha-synuclein loses its native structure. The structurally altered alpha-synuclein initiates the formation of dimers and trimers, followed by They form soluble oligomers and protofibrils and then deposit as fibrils. They may mature into aggregates.
[0011] Recently, exosomes have been shown to play a key role in the pathogenesis of various neurodegenerative disorders, including Parkinson's disease. It has been shown that it is involved in the propagation of folded proteins. For example, extracellular alpha- Synuclein has recently been shown to mediate the transfer of pathological alpha-synuclein from diseased neurons to healthy neurons. Misfolded alpha-synuclein is involved in the prion-like transmission of rhein. They could function as seeds to induce the aggregation of soluble alpha-synuclein.
[0012] A recent technique called real-time tremor induction conversion (RT-QuIC) has This technique exploits the ability of proteins to induce self-aggregation and has recently been used in patients with DLB and Parkinson disease. To detect pathological alpha-synuclein in CSF samples from patients with Malignant Lymphoma It has been used in a variety of applications (Fairfoul et al., 2016 (Non-Patent Document 3)). Recently, an alternative method to detect the presence of alpha-synuclein aggregates has been developed (Tan Protein Misfolding Cyclic Amplification (PMCA) (Herva et al. Although these methods are promising, it takes time to complete each assay. The time required to perform the analysis is long and the samples required for analysis (CSF or brain homogenate) are invasive. Because it requires an invasive procedure, patients with a high index of suspicion of disease (e.g., clinical symptoms and The use of these drugs is limited to patients with advanced disease (those with some markers of disease, or those in later stages of disease progression). [Prior art documents] [Non-patent literature]
[0013] [Non-Patent Document 1] Salvadores et al., 2014 [Non-Patent Document 2] Loov et al., 2016 [Non-Patent Document 3] Fairfoul et al., 2016 [Non-Patent Document 4] Herva et al., 2014 Summary of the Invention [Problem to be solved by the invention]
[0014] Diagnosis of early stage protein misfolding neurodegenerative disorders such as PD or DLB The tools need to be improved. [Means for solving the problem]
[0015] The present inventors have now surprisingly identified extracellular vesicle samples derived from PD or DLB patients. The presence of pathological alpha-synuclein in the nucleus may signal the disease and, importantly, the clinical Reliable for identifying or monitoring the risk of developing disease in people who are not yet symptomatic We have found that this can be used as a reliable marker for PD and DLB. The lipid composition of extracellular vesicles obtained from patients with Therefore, the present inventors have demonstrated that the genomic DNA of the present invention is significantly different from that of the genomic DNA of the present invention. This provides a novel means of monitoring and diagnosing the disease.
[0016] We used size exclusion chromatography (SEC) to identify pathological alpha-stimulatory Obtained extracellular vesicle (EV) samples used for the subsequent detection of nuclein. The use of SEC It is a very gentle means to enrich for EVs based on size rather than density of vesicles. This can result in the formation of protein complexes, aggregation of vesicles, and enrichment of other lipids present in the sample. This is advantageous because it does not pose the risk of However, the present invention may be equally used with EV samples obtained by other methods. An example of this is described in more detail below.
[0017] We hypothesized that the presence of pathological alpha-synuclein in EVs could be a signaling pathway that induces self-aggregation. The detection was achieved by utilizing the ability of known proteins to detect pathological alpha-synuclein. The method was used to assay EV samples for a faster and more sensitive assay protocol. As an example, the inventors have shown that a protocol can be provided for the known method, Using RT-QuIC to detect pathological alpha-synuclein in patient samples The time required for the synthesis of isolated EVs (without further optimization of the method) is approximately 1 Confirmed that the assay time can be shortened from 20 hours (current assay time) to 48-80 hours Further refinement of the assay will allow for a more rapid assay procedure.
[0018] The present invention uses RT-QuIC as a means to detect pathological alpha-synuclein. However, any other suitable method for detecting pathological alpha-synuclein may be used. As an alternative, non-limiting example, PMCA may be used (Herva et al. t al., 2014).
[0019] The inventors have demonstrated that the alpha-synuclein in several different biological samples (suitable for detection of pathological alpha-synuclein) EV samples from disease (including samples previously shown not to be It has been shown that it can be used reliably to detect, monitor, and differentiate between disease risk. The advantages include the use of biological samples that can be obtained by minimally invasive or non-invasive means (blood, Urine, saliva, etc.) have now been used as a source of EVs for detecting pathological alpha-synuclein. Thus, the present inventors have been able to detect disease (or risk of disease) using In response, researchers have developed more sensitive means to detect, monitor, and identify pathogens.
[0020] Furthermore, the inventors have used detection of pathological alpha-synuclein to identify disease-related disorders that may be associated with the onset of clinical symptoms. We demonstrate that it is possible to detect precursor alpha-synucleinopathy even before the onset of Thus, the methods described herein can be used to detect early signs of disease (or risk of disease). It can be used to detect, monitor and differentiate between stages of Parkinson's disease. Disease characteristics for early clinical evaluation of patients with alpha-synucleinopathy such as DLB or DLB This provides a more sensitive means of detecting the signs.
[0021] The present invention aims to identify pathological alpha-stimulatory genes in EV samples obtained from PD and DLB patients. However, the present invention is not limited to the detection of nuclein in pathological conditions. In some cases, other pathological prion-like proteins aggregate (e.g., into oligomers and fibrils). Advantageously, the detection of these prion-like pathological proteins is equally useful. The presence of each can be detected by their ability to induce self-agglutination. Therefore, methods such as RT-QuIC and PMCA (or modified versions thereof) are can be used for outgoing calls).
[0022] We also demonstrated that EVs obtained from CSF samples of PD or DLB patients The data confirmed that the patient's EVs showed significant lipid changes compared to controls. This suggests that significant lipid changes are important in the pathology. The lipid changes are in accordance with the methods of detecting pathological alpha-synuclein described herein. This may be part of the high sensitivity and specificity of the In-situ aggregation assays have demonstrated both modifications (changes in ceramide composition and synuclein folding) The changes in ceramide in pathological conditions may be very These changes are important for the development of cerebral cortex and are similar to those observed in brain tissue from patients with DLB and (For both patients with and without rheumatoid arthritis; unpublished data). Advantageously, the changes in lipid composition were especially Regarding rufasinucleinopathies, more specifically regarding PD and / or DLB , as biomarkers to detect, monitor, and identify disease (or risk of disease) It can be used.
[0023] In one aspect, the present invention relates to a method for treating a protein misfolding neurodegenerative disorder in a subject. An in vitro method for identifying or monitoring a pathogenic prion-like protein comprising detecting the presence of the pathogenic prion-like protein. and assaying a sample of extracellular vesicles from the subject for the presence of a pathogenic prion-like protein. The present invention provides a method of detecting a protein misfolding disorder, wherein the presence of the protein is indicative of a protein misfolding neurodegenerative disorder. In some cases, protein misfolding neurodegenerative disorders are caused by alpha-synuclein. It is a neuropathic disorder in which the pathological prion-like protein is alpha-synuclein.
[0024] In another aspect, the present invention provides a method for treating a subject suffering from a protein misfolding neurodegenerative disorder. An in vitro method for determining the risk of developing a disease characterized by the presence of a pathological prion-like protein. The method includes assaying a sample of extracellular vesicles from a subject for pathological prion-like proteins. The presence of proteins indicates that a subject has a high risk of developing a protein misfolding neurodegenerative disorder. In some cases, the method further includes detecting a protein misfolding neurodegenerative disorder. The sexual disorder is alpha synucleinopathy, and the pathological prion-like protein is alpha -synuclein.
[0025] In another aspect, the present invention provides a method for treating a patient suffering from a protein misfolding neurodegenerative disorder. suspected to have or are at high risk for developing protein misfolding neurodegenerative disorders The present invention provides an in vitro method for determining the presence of a pathological prion-like protein in a subject, The method comprises the steps of: (a) providing an extracellular vesicle sample from a subject; and (b) determining the presence of a pathological prion-like protein in the extracellular vesicle sample. In some cases, protein misfolding neurodegenerative disorders are caused by alpha-synuclein proteinases. Chi and the pathological prion-like protein is alpha-synuclein.
[0026] In another aspect, the present invention provides an in vitro method for selecting a treatment for a subject with a disease. The method includes detecting a pathological prion-like protein in an extracellular vesicle sample from a subject. determining the presence of a pathological prion-like protein; These results indicate that the present invention provides a method for treating neurodegenerative disorders that involve the folding of the nucleoside analogs .... In other words, protein misfolding neurodegenerative disorders are classified as alpha-synucleinopathy. and the pathological prion-like protein is alpha-synuclein.
[0027] Appropriately; a) Protein misfolding neurodegenerative disorders include Parkinson's disease and Lewy body syndrome and multiple system atrophy. the pathological prion-like protein is pathological alpha-synuclein; b) A protein misfolding neurodegenerative disorder is Creutzfeldt-Jakob disease. Yes; the pathological prion-like protein is a prion protein; c) The protein misfolding neurodegenerative disorder is Alzheimer's disease; The prion-like protein is pathological amyloid beta; d) Protein misfolding neurodegenerative disorders include Alzheimer's disease, frontotemporal Tauopaemia selected from the group consisting of tauopaedism, progressive supranuclear palsy, or corticobasal degeneration. the pathological prion-like protein is a pathological tau protein; e) The protein misfolding neurodegenerative disorder is Huntington's disease; The lyon-like protein is a member of the pathological huntingtin protein. ein); f) The protein misfolding neurodegenerative disorder is a motor neuron disease; The target prion-like protein is a pathogenic superoxide dismutase, c9orf72, and and valosin, as well as other prion-like proteins associated with motor neuron diseases. Selected from the group; g) Protein misfolding neurodegenerative disorder is dentatopallidal brolysia the pathological prion-like protein is a pathological atrophin protein; Or h) The protein misfolding neurodegenerative disorder is spinocerebellar ataxia; Ataxin-like proteins are pathological ataxins, and in some cases, pathological ataxins are It is selected from the group consisting of taxin-1, ataxin-2, and ataxin-3.
[0028] Suitably the subject is a human.
[0029] Suitably, the subject suffers from a protein misfolding neurodegenerative disorder, and In some cases, it is suspected that the patient suffers from a protein misfolding neurodegenerative disorder. The harm is alpha-synucleinopathy.
[0030] Suitably, the subject suffers from a protein misfolding neurodegenerative disorder. In some cases, protein misfolding neurodegenerative disorders are caused by alpha-synuclein proteinases. It's Chi.
[0031] Suitably, the subject is suffering from an early stage protein misfolding neurodegenerative disorder. In some cases, protein misfolding neurodegenerative disorders are caused by alpha synthase. It is a cranium.
[0032] Suitably, the extracellular vesicle sample may be CSF, blood, brain tissue homogenate, urine, saliva, or a combination thereof.
[0033] Suitably the blood sample is selected from the group consisting of plasma, serum, platelets and buffy coat. are selected.
[0034] Suitably, the extracellular vesicle sample is obtained using size exclusion chromatography.
[0035] Suitably, the method further comprises the steps of: i) providing a biological sample from a subject; and ii) Isolating extracellular vesicle samples from biological samples using size exclusion chromatography The process of obtaining the above.
[0036] Suitably, the presence of a pathological prion-like protein is detected using RT-QuIC or PMCA. In some cases, the pathological prion-like protein is detected as alpha-synuclein. It is.
[0037] In another aspect, the present invention relates to a method for treating protein misfolding neurodegeneration in a subject. For identifying or monitoring disorders or protein misfolding in a subject The present invention provides the use of in vitro extracellular vesicle samples to determine risk of developing a neurodegenerative disorder. In some cases, protein misfolding neurodegenerative disorders may be caused by alpha-synuclein. It is a nucleinopathy.
[0038] Suitably the use includes any of the features described herein.
[0039] In another aspect, the present invention provides a method for identifying or determining whether an alpha synucleinopathy exists in a subject. An in vitro method for monitoring is provided, comprising the steps of: a) Cer 32:1, Cer 33:1, and Cer 34:1 in the target extracellular vesicle sample. 34:1, Cer 34:2, Cer 37:1, Cer 38:1, Cer 38:2 ,Cer 39:1,Cer 39:2,Cer 40:1,Cer 40:2,Cer 41:1, Cer 41:2, Cer 40:1(OH), and Cer 40:2( assessing the amount of at least one ceramide species selected from the group consisting of: b) assessing the amount of at least one ceramide species by measuring the amount of at least one ceramide species; comparing with a reference value; wherein at least one ceramide species is greater than a reference value for at least one ceramide species. The assessment of ceramide species is indicative of alpha synucleinopathy.
[0040] In another aspect, the present invention provides a method for determining whether a subject is at risk of developing an alpha synucleinopathy. The present invention provides an in vitro method for determining whether a patient is a candidate for a pulmonary circulation disorder, the method comprising the steps of: a) Cer 32:1, Cer 33:1, and Cer 34:1 in the target extracellular vesicle sample. 34:1, Cer 34:2, Cer 37:1, Cer 38:1, Cer 38:2 ,Cer 39:1,Cer 39:2,Cer 40:1,Cer 40:2,Cer 41:1, Cer 41:2, Cer 40:1(OH), and Cer 40:2( assessing the amount of at least one ceramide species selected from the group consisting of: b) assessing the amount of at least one ceramide species by measuring the amount of at least one ceramide species; comparing with a reference value; wherein at least one ceramide species is greater than a reference value for at least one ceramide species. The assessed amount of ceramide species indicates that the subject is at high risk of developing alpha-synucleinopathy. Shows.
[0041] In another aspect, the present invention provides a method for treating a patient suspected of having alpha synucleinopathy, or Cer 32:1 in subjects at high risk for developing alpha-synucleinopathy. , Cer 33:1, Cer 34:1, Cer 34:2, Cer 37:1, Cer 38:1, Cer 38:2, Cer 39:1, Cer 39:2, Cer 40:1 , Cer 40:2, Cer 41:1, Cer 41:2, Cer 40:1(OH) and at least one ceramide selected from the group consisting of Cer 40:2(OH). An in vitro method for assessing the amount of a species is provided, the method comprising the steps of: (a) providing an extracellular vesicle sample from a subject; and (b) Cer 32:1, Cer 33:1, and Cer 34 in extracellular vesicle samples. :1, Cer 34:2, Cer 37:1, Cer 38:1, Cer 38:2, C er 39:1, Cer 39:2, Cer 40:1, Cer 40:2, Cer 4 1:1, Cer 41:2, Cer 40:1(OH), and Cer 40:2(OH ).
[0042] In another aspect, the present invention provides an in vitro method for selecting a treatment for a subject with a disease. and comprising the steps of: a) Cer 32:1, Cer 33:1, and Cer 34:1 in the target extracellular vesicle sample. 34:1, Cer 34:2, Cer 37:1, Cer 38:1, Cer 38:2 ,Cer 39:1,Cer 39:2,Cer 40:1,Cer 40:2,Cer 41:1, Cer 41:2, Cer 40:1(OH), and Cer 40:2( assessing the amount of at least one ceramide species selected from the group consisting of: b) assessing the amount of at least one ceramide species by measuring the amount of at least one ceramide species; comparing with a reference value; wherein at least one ceramide species is greater than a reference value for at least one ceramide species. 2. Assessing the amount of ceramide species that a subject will benefit from a treatment for alpha synucleinopathy It is shown that
[0043] Pertinently, alpha synucleinopathies include Parkinson's disease, Lewy body dementia, and and multiple system atrophy.
[0044] Suitably the subject is a human.
[0045] Suitably the subject is suffering from or suspected of suffering from alpha synucleinopathy. There is.
[0046] Suitably, the subject suffers from an alpha synucleinopathy.
[0047] Suitably the subject is suffering from early stage alpha synucleinopathy.
[0048] Suitably, the extracellular vesicle sample may be CSF, blood, brain tissue homogenate, urine, saliva, or a combination thereof.
[0049] Suitably the blood sample is selected from the group consisting of plasma, serum, platelets and buffy coat. are selected.
[0050] Suitably, the extracellular vesicle sample is obtained using size exclusion chromatography.
[0051] Suitably, the method further comprises the steps of: i) providing a biological sample from a subject; and ii) Isolating extracellular vesicle samples from biological samples using size exclusion chromatography The process of obtaining the above.
[0052] Suitably the reference value is obtained from a control sample or is a predetermined reference value.
[0053] In another aspect, the present invention provides a method for identifying or determining whether an alpha synucleinopathy exists in a subject. The present invention provides a method for monitoring or determining a subject's risk of developing an alpha-synucleinopathy. Cer 32:1, Cer 33:1, Cer 34:1, Cer 34:2 ,Cer37:1,Cer 38:1,Cer 38:2,Cer 39:1,Cer 39:2, Cer 40:1, Cer 40:2, Cer 41:1, Cer 41:2 , Cer 40:1(OH), and Cer 40:2(OH). The present invention provides the use of at least one extracellular vesicle ceramide species comprising:
[0054] Suitably the use includes any of the features described herein.
[0055] Throughout the description and claims of this specification, the words "comprise" and "contain" and variations thereof are meant to include, but are not limited to, other parts, additions, It is not intended (and does not) exclude any ingredients, integers, or steps.
[0056] Throughout this specification and the claims, the singular forms "a," "an," and "the" are used unless the context requires otherwise. In particular, where the indefinite article is used, the specification includes the plural unless the context requires differently. Unless a paragraph interpretation is necessary, it should be understood that plural as well as singular is intended.
[0057] Features, integers, characteristics described in relation to particular aspects, embodiments, or examples of the present invention , compound, chemical moiety, or group may be any other aspect, embodiment, or combination of any of the compounds described herein. or Examples, unless inconsistent.
[0058] Various aspects of the invention are described in further detail below. [Brief description of the drawings]
[0059] Embodiments of the invention are further described below with reference to the accompanying drawings.
[0060] [Figure 1]Representative electron microscopy images of extracellular vesicles purified from postmortem CSF are shown. [Diagram 2] Representative images of TRPS analysis results showing vesicle size and concentration are shown. [Diagram 3] Representative images of Western blot analysis and immunoelectron microscopy of the presence of exosome markers in samples are shown. [Figure 4] 1 shows immunogold labeling of alpha-synuclein associated with the membrane of extracellular vesicles purified from postmortem cerebrospinal fluid. The graph represents the abundance of different vesicle sizes labeled with alpha-synuclein. Data was pooled across all samples and therefore represents a mixed population. [Diagram 5] Internal alpha-synuclein labeling and the various vesicle sizes labeled with alpha-synuclein are shown. Data was pooled across all samples and therefore represents a mixed population. [Figure 6] Changes in ceramide species identified in EVs from alpha-synucleinopathy patients compared to controls. Positive ion mode data. [Figure 7] Changes in ceramide species identified in EVs from alpha-synucleinopathy patients compared to controls. Negative ion mode data. [Figure 8] 1 shows purification and analysis of frontal cortex extracellular vesicles. [Figure 9] Western blot analysis of purified frontal cortex extracellular vesicle markers. The absence of calnexin and porin indicates the purity of the fractions and the lack of contamination with cellular and synaptic material. LBD-Lewy Body Disease. MT, WT-mutant, wild type. [Figure 10] Western blot analysis of exosome markers is shown. [Figure 11] 1 shows the results of alpha-synuclein ELISA on lysed frontal cortex vesicles. [Figure 12]We show the results of RT-QUIC using processed unprocessed postmortem CSF, and purified extracellular vesicles. By using postmortem CSF-derived vesicles, we were able to detect Parkinson's disease pathology even before clinical symptoms occurred (the exponential line indicates reliable detection of disease features) (see prodromal synucleinopathies). PD-Parkinson's disease, DLB-Dementia with Lewy Bodies, PDD-Parkinson's disease dementia. Compared to the original method using processed unprocessed lumbar CSF (presented in Fairfoul et al. 2016), we were able to detect the positive signal of the assay earlier. This holds the promise of making the assay faster (i.e., 48-80 h (without additional optimization) compared to 120 h (current assay time)). [Figure 13] 1 shows Parkinson's disease processed unprocessed plasma, platelets, and buffy coat RT-QUIC results. [Figure 14] The results of RT-QUIC using purified platelet vesicles are shown. [Figure 15] 1 shows the results of RT-QUIC using purified plasma vesicles. [Figure 16] TEM images of extracellular vesicles purified from human urine are shown. [Figure 17] TEM images of extracellular vesicles purified from human postmortem CSF using ultracentrifugation. [Figure 18] Results of protein aggregation assays using extracellular vesicles isolated by ultracentrifugation on CSF samples from Dementia with Lewy Bodies and Parkinson's Disease. Measurements were performed every 15 minutes over a period of 115 hours. PD-Parkinson's Disease, DLB-Dementia with Lewy Bodies, UC-Ultracentrifugation. [Figure 19] Results of a protein aggregation assay using extracellular vesicles isolated by ultracentrifugation for healthy control samples are shown. C - control, UC - ultracentrifugation. [Figure 20]Results of protein aggregation assays using Parkinson's disease dementia brain homogenates, dementia with Lewy bodies frontal cortex extracellular vesicles, and control frontal cortex extracellular vesicles. PDD-Parkinson's disease dementia, DLB-dementia with Lewy bodies, C-control. [Figure 21] Blinded analysis of urinary extracellular vesicle analysis is shown. Donors were clinically diagnosed as follows: Urine 2 - control; Urine 4 - PSP; Urine 5 - MSA; Urine 6 - PSP. These data show that alpha-synucleinopathy can be clearly identified from urine samples (see Urine 5 - MSA, where both repeats gave positive results in the alpha-synuclein protein aggregation assay compared to control). Urine samples were taken from living patients who had a clinical diagnosis but had not yet undergone a neuropathological diagnosis. Based on the results shown in FIG. 21, we suspect that there is a small amount of alpha-synuclein pathology in the patient in Urine 4, since both repeats are positive, but the signal appears later compared to MSA Urine 5. Urine 6 is a possible false positive, since one of the repeats is negative (i.e., the repeats do not show a consistent pattern). [Figure 22] A blinded analysis of urinary extracellular vesicles is shown. Donors were clinically diagnosed as follows: urine 7 - control; urine 9 - PSP; urine 10 - PSP. Urine samples were taken from living patients who had a clinical diagnosis but had not yet performed a neuropathological diagnosis. Therefore, some controls may in fact have some pathology but have not yet shown clinical symptoms (see especially urine 7, where one of the repeats showed some positive signal in the alpha-synuclein protein aggregation assay, whereas this may be a false positive since one of the repeats was negative (i.e. the repeats do not show a consistent pattern)). Detailed Description of the Invention
[0061] The present inventors have now surprisingly identified extracellular vesicle samples derived from PD or DLB patients. The presence of pathological alpha-synuclein in the blood identifies the disease (or the risk of developing the disease). It has been discovered that these compounds can be used as reliable markers for identifying or monitoring inflammatory bowel disease. In addition, the lipid composition of extracellular vesicles obtained from PD and DLB patients was similar to that of controls ( In particular, we demonstrated that the ceramide composition of the extracellular vesicle membrane is significantly different from that of the extracellular vesicle membrane. The inventors have provided a novel means of detecting, monitoring and diagnosing disease.
[0062] Inventors for identifying or monitoring protein misfolding neurodegenerative disorders in subjects An in vitro method for detecting extracellular vesicles from a subject for the presence of a pathological prion-like protein. Assaying the sample, the presence of the pathological prion-like protein is detected by detecting the protein mimetics. Methods are provided herein that are indicative of a folding neurodegenerative disorder.
[0063] For those skilled in the art, the presence of a particular pathological prion-like protein in an EV sample can be used to identify a particular Identifying (i.e., corresponding) protein misfolding neurodegenerative disorders It is clear that pathological prion-like proteins and their corresponding protein misfolded The association of EV sampling with neurodegenerative disorders is well known in the art. If the specific pathological prion-like protein present in the sample is alpha-synuclein, This will allow researchers to identify specific (i.e., corresponding) protein misfolding neurodegenerative disorders. However, alpha-synucleinopathies, such as Parkinson's disease or dementia with Lewy bodies, Specific pathological prion-like proteins and their corresponding protein mismatches are identified. Other examples of folding neurodegenerative disorders are provided throughout this application. applies to all embodiments described herein.
[0064] Also, the present invention relates to a method for determining a subject's risk of developing a protein misfolding neurodegenerative disorder. The in vitro method comprises screening cells from a subject for the presence of a pathological prion-like protein. and assaying the exovesicle sample for the presence of a pathological prion-like protein, A method is disclosed that indicates high risk of developing protein misfolding neurodegenerative disorders This is provided in the documentation.
[0065] Protein misfolding neurodegeneration in a subject from analysis of a suitable sample. The identification of the disorder may be based in particular on clinical evaluation of symptoms and / or other diagnostic criteria, such as neurophysical evaluation of the subject. When performed in conjunction with the method, it is equivalent to diagnosing a condition. "Identification of Protein Misfolding Neurodegenerative Disorders" (or equivalent phrase) and "Protein Misfolding Neurodegenerative Disorders" (or equivalent phrase) "(or equivalent phrase)" are used interchangeably herein. Used.
[0066] Monitoring protein misfolding neurodegenerative disorders in subjects over time can provide insight into the progression of disease. Progression (e.g., worsening of a disease state or disease symptoms) or progression of a disease (e.g., over a period of treatment) Such monitoring, of course, is essential for the early identification of symptoms or improvement in symptoms. The method involves the collection of samples over time. The test may be repeated at one or more time intervals, and the results are used to determine the target tangents. Monitor the onset, progression, or improvement of protein misfolding neurodegenerative disorders over time Here, the amount of pathological prion-like protein in the subject's EV sample is compared. The change in the level of the protein misfolding neurodegenerative disorder in the subject is indicative of a change in the progression of the protein misfolding neurodegenerative disorder in the subject.
[0067] Pathological progression of a disease over time is detected when the results of two or more time intervals are compared. In other words, the method can be repeated multiple times to obtain an increased amount of prion-like protein. If implemented, the amount of pathological prion-like protein detected at the later time intervals would be greater than that detected at the earlier time intervals. A greater amount detected over a time interval may indicate disease progression. The "increase" in protein amount is consistent with the method using the same subjects (and comparable EV sample types). If the test was performed earlier (i.e., at an earlier time interval), the pathogenic prion-like protein Subsequent cases where the protein was not detected (i.e., not present at detectable levels) The present invention includes detection of a pathological prion-like protein at a time interval of 100 s.
[0068] Suitable time intervals for monitoring disease progression can be readily identified by one of skill in the art, and The specific protein misfolding that will be monitored by the As a non-limiting example, the method can be used to monitor the progression of Parkinson's disease. If so, the period is repeated at least every six months, or at least annually, or at least every other year. Good too.
[0069] Improvement in a disease state or symptom (e.g., over a period of treatment) is seen over two or more time intervals This can be shown by a reduction in the amount of pathological prion-like protein detected when compared. In other words, if the method is performed multiple times, pathological priors detected at later time intervals may be eliminated. The amount of cytochrome P450-like protein detected is less than that detected at earlier time intervals (i.e., decreased Therefore, when the pathogenic prion-like protein is present in the patient, the improvement of the pathological condition can be observed. The "reduction" in the amount of prion-like protein indicates that the pathological prion-like protein is more abundant in the same subject (and in the equivalent EV sample). type) was not detected (i.e., prion-like proteins were not detected at the later time points). Pathological prion-like proteins in the early time intervals were not detectable or were absent The method includes repeating the method at subsequent time intervals following detection of the protein.
[0070] Improvement in a disease state or symptom (e.g., over a period of treatment) may also be considered to be a symptom of a disease or condition (e.g., over a period of treatment). The levels of pathological prion-like protein observed without the treatment or with equivalent controls were compared. A slow increase in pathological prion-like protein over time, or This can be demonstrated by a stabilization of target prion-like protein levels.
[0071] Suitable time intervals for monitoring improvement of a disease state or symptom (e.g., during treatment of a subject) include: Specific protein misfoldings can be readily identified and monitored by one of skill in the art. As a non-limiting example, the method may be determined by the type of neurodegenerative disorder. When monitoring Parkinson's disease (e.g., during treatment of a subject with Parkinson's disease), The test may be repeated at least every six months, or at least annually, or at least every other year.
[0072] Determining the risk of a subject to develop a protein misfolding neurodegenerative disorder includes determining whether the subject is at risk for developing a protein misfolding neurodegenerative disorder. This will help identify the condition as early as possible. This allows for early intervention and / or initiation of treatment at an early stage in the progression of the disease. Also, high-risk individuals (i.e., those who are highly likely or likely to develop the disease) (those with a higher risk of infection) so that treatment or preventive measures can be implemented at the earliest opportunity. In this context, the inventors provide a means for the method described herein. Using this method, it is possible to identify precursor alpha-synucleinopathy even before clinical symptoms occur. It has been shown that the method described herein can be successfully used to detect , to detect, monitor, and identify early stages of disease (or risk of disease); Therefore, it is possible to develop early clinical treatment for alpha-synucleinopathy patients such as Parkinson's disease. Provides a more sensitive means of detecting disease characteristics for evaluation.
[0073] The methods described herein include treating a subject with protein misfolding neurodegeneration. or to identify or monitor a subject for a neurodegenerative disorder caused by protein misfolding. It provides a novel means of determining the risk of developing a disorder.
[0074] As used herein, a "protein misfolding disorder" refers to a class of disorders. Damage (proteinopathy, proteopathy, protein structural disorder, or protein misfolding) This refers to a condition called idiopathic glaucoma (also known as idiopathic glaucoma), in which certain proteins have the structure They disrupt the function of the body's cells, tissues, and organs by becoming abnormal in some way. In this case, the pathological protein does not fold into its normal configuration and remains in this misfolded state. In some cases, the protein may become toxic in some way (gain of toxic function), or It may lose normal function.
[0075] As used herein, a "protein misfolding neurodegenerative disorder" refers to a neurodegenerative disorder that affects the nervous system. of protein misfolding disorders, particularly those associated with neuronal degeneration in the brain. This group of disorders includes Parkinson's disease (including Parkinson's disease dementia), Dementia with Bee bodies, multiple system atrophy, Creutzfeldt-Jakob disease, Alzheimer's disease, Oopathies (Alzheimer's disease, frontotemporal lobar degeneration, progressive supranuclear palsy, and corticobasal Nuclear degeneration, Huntington's disease, motor neuron disease, dentatopallidal brolysian atrophy, spinocerebellar ataxia, and many others (Salvadores e (t al., 2014). For each of these protein misfolding neurodegenerative disorders, Specific pathological prion-like proteins have been identified that play a central role in disease Ta.
[0076] For example, alpha-synucleinopathy, a protein misfolding neurodegeneration Disorders (e.g., Parkinson's disease (including Parkinson's disease dementia), dementia with Lewy bodies, and multiple system atrophy), the pathological prion-like protein is a pathogenic alpha-synuclein In humans, this is found in NCBI GenBank or UniProt Identification using Gene ID: 6622; Protein ID: P37840) It is possible.
[0077] Synucleinopathies are characterized by the loss of alpha-synuclein in selective populations of neurons and glia. A set of neurodegenerative disorders associated with the deposition of fibrillar aggregates of rhein. The substances are found in the soma of neurons, such as Lewy bodies (LB), or in Parkinson's disease (PD). in dystrophic neurites in diseases such as dementia with Lewy bodies (DLB), or Found in glial cytoplasmic inclusions in multiple system atrophy (MSA). Parkinson's disease. Synucleinopathies such as dementia with Lewy bodies and multiple system atrophy are clinically well-defined. The details of which can be found in the following references: For PD, McKeith et al. 2017; for PD, Postuma et al. l.2015;for MSA, Kim et al.2015.
[0078] As used herein, "pathological alpha-synuclein" refers to the .2014 and Tuttle et al.2016. Refers to the alpha-synuclein protein having a structural conformation. As described elsewhere herein, pathological alpha-synuclein is They tend to aggregate into ter-sheet fibrils and initiate the formation of dimers and trimers. Then, soluble oligomers and protons are formed, which are deposited as fibrils and mature as aggregates. Thus, pathological alpha-synuclein may form rotofibrils. Direct detection by the presence of lupha-synuclein / alpha-synuclein aggregates Several methods for detecting aggregation of proteins of interest are known, including immunoassays. These include noEM, RT-QuIC, and PMCA.
[0079] As a further example, protein misfolding neurodegenerative disorders such as Creutzfeldt-Jakob disease In the case of Creutzfeldt-Jakob disease, the pathological prion-like protein is a pathological prion protein, This is a gene that has been identified in humans using NCBI GenBank or UniProt (Gene ID :5621; Protein ID:P04156). As used herein, "pathological prion protein" refers to a Gallagher-Jone s M Unusual structural conformations, as described in et al. Pathological prion proteins are proteins that aggregate to become infectious prions. misfold into a self-propagating conformation that tends to form cyclic structures. Therefore, pathological prion protein is a prion protein aggregate / prion protein aggregation Aggregation of the protein can be detected directly by its presence. Methods are well known and include immunoEM, RT-QuIC, and PMCA.
[0080] Creutzfeldt-Jakob disease is clinically well-defined and is described in detail in Zerr et al. et al. 2002.
[0081] As a further example, protein misfolding neurodegenerative disorders such as Alzheimer's disease In some cases, the pathological prion-like protein is pathological amyloid beta, which in humans The gene was identified in the NCBI GenBank or UniProt (Gene ID: 351; As used herein, the protein ID: P05067 can be used to identify the The so-called "pathological amyloid beta" or "Aβ" is found in the brains of people with Alzheimer's disease. This refers to a peptide of 36 to 43 amino acids that is the main component of amyloid plaques. is cleaved by beta-secretase and gamma-secretase to generate Aβ. It is derived from the amyloid precursor protein (APP). Aβ molecules aggregate and form flexible, Amyloid beta forms soluble oligomers that are toxic to neurons. The structure of Aβ is described in Schmidt et al. 2015. Aβ is an Aβ aggregate / It can be detected directly by the presence of Aβ aggregates. Several methods are known, including immunoEM, RT-QuIC, and PMCA. can be done.
[0082] Alzheimer's disease is clinically well-defined, as detailed in Desai et al. al.2005; McKhann et al.2011; and Dubois et al. al.2014.
[0083] As a further example, protein misfolding neurodegenerative disorders include tauopathies (e.g. For example, Alzheimer's disease, frontotemporal lobar degeneration, progressive supranuclear palsy, or corticobasal degeneration. ), the pathological prion-like protein is a pathological tau protein, which is a human In NCBI GenBank or UniProt (Gene ID: 4137 ;Protein ID: P10636). The “pathological tau protein” used in this study was defined as the protein 7 refers to tau protein with an abnormal structural conformation, as described in Pathological tau protein misfolds into a self-propagating conformation that is prone to aggregation. Therefore, pathological tau protein is tau protein aggregates / tau protein complexes. The protein can be detected directly by the presence of protein aggregates. Several methods are known, including immunoEM, RT-QuIC, and PMCA. can be done.
[0084] Alzheimer's disease, frontotemporal lobar degeneration, progressive supranuclear palsy, or corticobasal degeneration, etc. The tauopathies are clinically well-defined and are described in detail in, for example, Hoglin et al. ger GU et al.2017;Gil et al.,2010(frontotemporal lobe change ), and Alexander et al., 2014 (on corticobasal degeneration) The above can be found in the literature (regarding the disease).
[0085] As a further example, a protein misfolding neurodegenerative disorder is Huntington's disease. In the present case, the pathological prion-like protein is a pathological huntingtin protein, which is In the study, the NCBI GenBank or UniProt (Gene ID: 306 4; Protein ID: P42858). The term "pathological huntingtin protein" used in this study refers to an unstable expansion within the huntingtin gene. Has an unusual structural conformation generated by a long trinucleotide repeat It refers to the huntingtin protein, which contains polyglutamine repeats within the protein product. Pathological huntingtin protein is translated as Proteins misfold into a self-propagating conformation that is prone to aggregation. Pathological huntingtin protein is huntingtin protein aggregates / huntingtin protein The presence of protein aggregates can be detected directly by the presence of protein aggregates. Several methods are known, including immunoEM.
[0086] Huntington's disease is clinically well defined, the details of which are well known to those skilled in the art. (See, for example, Pagan et al., 2017).
[0087] As a further example, protein misfolding neurodegenerative disorders include motor neuron disease If so, the pathological prion-like protein is a pathological superoxide dismutase (SOD 1), c9orf72, and valosin, which are selected from the group consisting of and identified using the following NCBI GenBank or UniProt ID numbers: SOD1 (Gene ID: 6647, Protein ID: P00 441);c9orf72(Gene ID:203228, Protein ID:Q 96LT7); Valosin (Gene ID: 7415, Protein ID: P550 72). As used herein, the term "pathological superoxide dismutase, c9orf72" refers to "Valosin" and "valosin" have unusual structural conformations described in the following references: tion, superoxide dismutase, c9orf72, and valosin :SOD1:Sangwan et al.2017;c9orf72:Guo et al. al. 2018; and Valosin: Basso et al. 2013. Oxide dismutase, c9orf72, and valosin are self-propagating proteins prone to aggregation Pathological superoxide dismutase, c9 orf72, and the valosin protein are involved in the superoxide dismutase, c9orf 72, and valosin protein aggregates / superoxide dismutase, c9orf 72 and can be detected directly by the presence of aggregates of the valosin protein. Other rare forms of neuronal disease involve the aggregation of other prion-like proteins known to those skilled in the art. Several methods are known to detect the aggregation of proteins. Examples include immunoEM.
[0088] Motor neuron diseases are clinically well defined, the details of which are well known to those skilled in the art. (see, e.g., Traynor et al., 2000).
[0089] As a further example, protein misfolding neurodegenerative disorders such as dentatopallidorub In the case of R. atrophy, the pathological prion-like protein is a pathological atrophin protein. It is a protein that is found in humans in NCBI GenBank or UniProt Identified using Gene ID: 1822; Protein ID: P54259) As used herein, a "pathological atrophin protein" refers to a Atrophyx, which has an unusual structural conformation described by et al. Pathological atrophin proteins are self-replicating atrophin proteins that tend to aggregate. The pathological atrophin protein misfolds into the atrophin conformation. It can be detected directly by the presence of atrophin / atrophin protein aggregates. Several methods for detecting protein aggregation are known, including immunoEM. Examples include:
[0090] Dentopallidal Broiler-Luisian atrophy is clinically well-defined and its details are well known to those of skill in the art (see, e.g., Wardle et al., 2009).
[0091] As a further example, a protein misfolding neurodegenerative disorder is spinocerebellar ataxia. In these cases, the pathological prion-like protein is ataxin-1, ataxin-2, and ataxin-3. Pathological ataxins such as synthin-3, which are identified in humans as pathological ataxins in the NCBI GenBan k or Uniprot (for ataxin 1 (Gene ID: 6310, Prot for ataxin 2 (Gene ID: 6311, P protein ID:Q99700; ataxin 3 (Gene ID:428 7, Protein ID: P54252) can be used to identify the protein. The term "pathological ataxin" used in this paper is described in Ruggeri et al. 2015. This refers to ataxin proteins with abnormal structural conformations that have been reported in pathological ataxin. Taxin proteins misform into self-propagating conformations that are prone to aggregation. Pathological ataxin protein is ataxin protein aggregates / ataxin proteins. The presence of protein aggregates can be detected directly by detecting the aggregation of the protein. Several methods are known, including immunoEM.
[0092] Spinocerebellar ataxias are clinically well-defined, the details of which are well known to those skilled in the art. (see, for example, van de Warrenburg et al., 2014).
[0093] As used herein, the term "subject" refers to a mammal. Thus, a subject can be, for example, , dogs, cats, horses, cows, pigs, guinea pigs, etc. The subject may be a human. Where the subject is a human, the subject may be referred to herein as a patient. "Individual" and "patient" are used interchangeably herein.
[0094] The subject may be symptomatic (e.g., the subject may be diagnosed with protein misfolding). The subject may be asymptomatic (e.g., the subject exhibits symptoms associated with a neurodegenerative disorder), or the ... Although the patient does not exhibit symptoms associated with a protein misfolding neurodegenerative disorder, may show mild biochemical changes associated with adverse effects.
[0095] The subject is diagnosed with symptoms of a protein misfolding neurodegenerative disorder. You may have this, be at risk for developing it, or exhibit this condition.
[0096] The subject suffers from a protein misfolding neurodegenerative disorder as described herein. They may have or be suspected of having the disease (e.g., because they present with symptoms or a medical history). or these are suggestive).
[0097] Thus, in some instances, the subject is diagnosed with a protein misfolding neurodegenerative disorder. In certain instances, the subject is suffering from early stage protein misfolding. As an example of the early stages of the disease, subjects develop protein misformations. These may be prodromal stages of a growing neurodegenerative disorder, in which early symptoms of the disease are present but However, sufficient symptoms have not yet appeared to diagnose the disease.
[0098] As mentioned above, each of these disorders is clinically well-defined and therefore should be considered in clinical diagnosis. Identify risk factors and symptoms (including early symptoms) for diagnosis or associated with each disorder. At least one means for doing so is well known to those of skill in the art.
[0099] The methods described herein include providing, obtaining, and assaying an extracellular vesicle sample from a subject. and / or analyzing the step of
[0100] Extracellular vesicle (EV) samples can be obtained from any suitable biological sample of the subject. The methods described herein can be used to detect, detect, and / or measure the concentration of a substance in a sample (e.g., a biopsy, drawing a blood sample, urine or may include obtaining a biological sample from the subject (such as by sampling saliva). Methods for obtaining biological samples (e.g., blood samples) from animals are well known and include, for example, methods used for phlebotomy. Examples of established techniques include:
[0101] Generally, the methods described are performed using a sample that has already been obtained from a subject. It is an in vitro method (i.e., a sample is provided for the method and is extracted from a subject) Steps performed to obtain the sample are not included as part of the method.
[0102] As used herein, a "biological sample" or "sample" refers to a sample obtained from a subject. For purposes herein, a sample refers to a sample derived from a subject. The sample may be a tissue sample (e.g., a biopsy, such as a brain biopsy) or a liquid sample. Suitable samples include cerebrospinal fluid (CSF), blood (whole blood or its components, e.g. For example, plasma, serum, platelets, buffy coat, or a combination thereof), brain tissue homogenate, Examples of samples include urine, saliva, or any combination of the above. Each of these proteins is useful for detecting protein misfolding neurodegenerative disorders. or have been shown to be potentially useful samples (e.g., Loov et al., 2013). 016;Mollenhauer et al.,2011;Danzer et al. ., 2012; and Luk et al., 2016). (or blood components such as plasma, platelets, serum, buffy coat, etc.) Methods for isolating IL-18 from whole blood are well known in the art and are described herein. This can be routinely used to obtain an appropriate biological sample for analysis.
[0103] The methods described herein involve the collection of extracellular vesicles (EVs) obtained from a biological sample of a subject. The method relates to the use of the sample. The method includes the steps of obtaining an extracellular vesicle sample from a biological sample. Alternatively, the method may include carrying out a step of: The method steps themselves may include obtaining extracellular vesicles from a biological sample (e.g., The method does not include any purification, isolation, or enrichment steps.
[0104] EV samples can be obtained using any suitable method for obtaining EVs known in the art. may be obtained (as part of the method or prior to commencing the method) by one or more Examples of suitable methods for obtaining EV samples are provided by Lobb et al., 2015; and Boing et al., 2014. Suitable methods for this purpose include differential centrifugation, density gradient ultracentrifugation, and size exclusion chromatography. Raffi is mentioned.
[0105] Thus, in one example, the method described herein comprises the steps of: i) providing a biological sample from a subject; and ii) Isolating extracellular vesicle samples from biological samples using size exclusion chromatography The extracellular vesicle sample is then subjected to a step of subjecting the sample to a purification process as described elsewhere herein. Then, the samples are assayed for the presence of a pathological prion-like protein.
[0106] The inventors advantageously use size exclusion chromatography (SEC) to analyze the chromatographic properties of brain tissue. From suitable biological samples such as homogenates, CSF, plasma, or platelet samples, It was confirmed that the V sample could be obtained. Size exclusion chromatography was performed to isolate EVs. It is superior to differential centrifugation and density gradient ultracentrifugation, which are the most widely used methods for isolating There are several advantages to using this method, as discussed in Boing et al., 2014. Thus, with SEC there is no risk of protein complex formation or vesicle aggregation. Furthermore, the high viscosity of plasma affects the recovery of vesicles isolated by differential centrifugation. However, this does not affect vesicle recovery by SEC. Compared to density gradient ultracentrifugation, The vesicles are compatible with buffers of physiological osmolality and viscosity, allowing the biological properties of the vesicles to be optimized. The company’s legality appears to be unaffected after the separation by the SEC. This allows separation of overlapping density contaminants such as cholesterol (this is known as density gradient ultracentrifugation) (not possible using isolation).
[0107] SEC separates materials based on size. For example, a pore with a diameter of about 75 nm (Reviewed in Boing et al., 2014), the path through the beads is tortuous. Sepharose beads in a column may also be used. As a result, particles that can enter the beads are slowed down. Any particles that are too small (e.g., larger than 75 nm in this example) cannot enter the beads. The pore volume of the Sepharose (e.g., S The method was directly verified (confirmed by EM) using epharose CL-2B. It can be used to separate EVs with diameters of 70 nm or more from smaller contaminants in a sample. It was confirmed that it is possible to use beads with smaller pores and to obtain smaller sizes. Vesicles may be isolated (although this may entail increased contamination). The pore size of the column (as well as the column height, column diameter, and sample volume) It may be tailored / optimized for the specific purpose required.
[0108] Any suitable methodology for size exclusion chromatography may be used to determine the identity of the compounds described herein. Suitable methodological details are given below, as non-limiting examples: Please refer to the following.
[0109] The biological samples of interest (e.g., CSF, plasma, platelets) may be fresh or The biological sample may be refrigerated or frozen. If frozen, the biological sample may be The gel may be thawed, for example on ice, prior to band exclusion chromatography.
[0110] If the biological sample is a tissue sample (fresh, refrigerated, frozen, or thawed), The mixture may be homogenized prior to size exclusion chromatography. Details of suitable protocols are provided in the Examples section below.
[0111] The biological sample may be subjected to size exclusion chromatography (e.g., to determine whether the material in the sample is The mixture may be vortexed (to encourage the mixture to go into solution or to stay in solution).
[0112] The biological sample may be pre-cleared by centrifugation, e.g., for CSF. Preclearing consisted of three consecutive tests at 1500g, 3000g, and 10,000g. The length of each step is typically 10 minutes; for plasma, preclearing The experiment included three consecutive steps of 1500g, 3000g, and 3000g, with the duration of each step being The duration is typically 10 minutes. After each step, the supernatant (liquid portion) is retained and used for the next step. It is used.
[0113] A typical commercially available SEC column has a maximum or optimal liquid loading capacity. Recleared biological samples (i.e., those present at the end of the preclearing step) Supernatant) if its volume is greater than the maximum or optimal loading capacity of the SEC column, Samples should be diluted by any appropriate means (e.g., centrifuge) until optimal or maximum loading capacity is achieved. For example, the cells may be concentrated using VivaSpin centrifugal concentrators (Sartorius). For example, we loaded about 500 μl of sample onto the SEC column. Therefore, if more than 500 μl of precleared sample was available, In this study, we used VivaSpin centrifugal concentrators ( The samples were concentrated to approximately 500 μl using a centrifuge tube (Sartorius).
[0114] The precleared (and possibly enriched) sample is then The SEC column may be loaded according to the instructions of Carr. An EC column may be used. As an example, the CSF and plasma samples described herein Regarding the qEV (Izon Science) standard 500 μl SEC column used in the In this study, we performed a 500 μl run of each precleared sample on a separate column. The first 6x50 was loaded onto a 1000 ml centrifuge tube and eluted using PBS. The 0 μl fraction (collected as a total of 3 ml fractions) is the void volume, and EVs are collected in fractions 7, 8, and In this example, all three EV fractions were collected in one tube. This may be done.
[0115] EV samples may optionally be concentrated after SEC. Any suitable methodology for reducing the amount of chromatographic information may be used. EV fraction (approximately 1500 μl) was purified using VivaSpin2 (Sartorius). The fraction was concentrated to 500 μl.
[0116] EV samples may be assayed (or analyzed) immediately or stored in an appropriate manner. The cells may be frozen or stored at, for example, -80°C.
[0117] As described elsewhere herein, EV samples are obtained from biological samples. This indicates that EVs are enriched (i.e., the concentration of EVs is higher than that of the biological sample from which they were generated ( (higher) processing compared to the concentrations of EVs in CSF, blood, urine, and plasma In this context, "enriched" or "enriched" refers to a biological sample. The proportion of EVs contained within the sample was increased relative to the other components of the sample. Enrichment refers to the number of EVs before and after processing of a sample. Any increase in the relative number of EVs compared to other components of the sample may be measured by Enrichment and / or purity are considered to be enriched based on the biological sample from which the EV sample was generated. sample (e.g., unprocessed or precleared sample) The concentration of EVs may be measured in terms of concentration relative to the concentration of EVs in a biological sample (e.g., The concentration of EVs in the untreated or precleared samples was At least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 9 5% higher. Enrichment and / or purity may be measured in terms of EV molecule counts and may be expressed as a percentage of the sample. The EV samples were generated from biological samples (e.g., unprocessed samples). , or pre-cleared samples), approximately or at least Also about 2x, 3x, 4x, 5x, 10x, 15x, 20x, 25x, 30x, 35x, 40 x, 45x, 50x, 55x, 60x, 65x, 70x, 75x, 80x, 85x, 90 x, 95x, 100x, 110x, 120x, 130x, 140x, 150x, 160x , 170x, 180x, 190x, 200x, 210x, 220x, 230x, 240x , 250x, 260x, 270x, 280x, 290x, 300x, 325x, 350x , 375x, 400x, 425x, 450x, 475x, 500x, 525x, 550x , 575x, 600x, 625x, 650x, 675x, 700x, 725x, 750x , 775x, 800x, 825x, 850x, 875x, 900x, 925x, 950x , 975x, 1000x, 1100x, 1200x, 1300x, 1400x, 1500 x, 1600x, 1700x, 1800x, 1900x, 2000x (same as double), and and are enriched to the fullest extent possible within them.
[0118] The level of enrichment is measured using EM and tunable resistive pulse sensing (TRPS) It can be requested.
[0119] The EV sample (in other words, the EV-enriched sample) contains 100% pure extracellular It does not have to be a vesicle.
[0120] Preferably, the EV sample is free of a minimal amount of contaminating cellular or extracellular content (e.g. For example, cellular or extracellular proteins, lipids, carbohydrates, and lipoproteins that are not associated with EVs In other words, the EV sample may be composed mainly of EVs. "Minimum amount" means less than 10% (concentration) of impurities, less than 5% (concentration), less than 2%, less than 1% It may contain impurities at less than 0.5%, less than 0.25%, less than 0.1%, etc. The concentration does not have to be 0%. Contamination levels can be determined using EM.
[0121] The EV sample may be an isolated sample containing substantially pure EVs. The isolated sample may be isolated from any EV-containing biological sample. The terms "substantially pure" or "substantially pure" when referring to an isolated sample containing pure EVs "Substantially pure" means that the percentage of EVs in a population is greater than or equal to the percentage of EVs in the target tissue or bloodstream The biological sample from which the EV sample was generated (e.g., unprocessed sample) significantly higher than those found in the precleared sample) Typically, the phenotype of EVs in an isolated sample containing substantially pure EVs is determined. The percentage is at least about 50%, preferably at least about 60%, of the total sample. 0%, 75%, more preferably at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%.
[0122] Extracellular vesicles have been well characterized and well defined in the art. It has been widely accepted that the cell Extracellular vesicles have been isolated from several body fluids. They have been implicated in stem cell maintenance, immune surveillance, and It has been shown to play an important role in regulating physiological processes, including the regulation of blood clotting and It has also been shown that extracellular vesicles play an important role in the pathology underlying several diseases. has been shown to play an important role.
[0123] In contrast to synaptic vesicles, extracellular vesicles are released intact from neurons and They can be shed from multivesicular bodies (MVBs) derived from cytoplasmic vesicles or directly from the plasma membrane. When released into the extracellular space, they form from the inner cell membrane and can bud out. They are called exosomes or ectosomes (or microsomes), depending on whether they are formed from the outer cell membrane or the extracellular membrane. These cells are called vesicles and are taken up by other cells via endocytosis or fusion. can be.
[0124] Extracellular vesicles are classified according to their cellular origin, biological function, or based on their biogenesis. They are classified as cyclohexylglycerols (reviewed in Andaloussi et al., 2013). The three major classes of extracellular vesicles determined by ELISA are exosomes, microvesicles, and apoptotic vesicles. The first two are cytoplasmic bodies within the biological sample (and therefore the EV sample derived from it). EV markers are well known in the art. Examples of genome markers include tetraspanins (such as TSPAN29 and TSPAN30), ESCRT components, PDCD6IP, TSG101, flotillin, and MFG Examples of microvesicle markers include integrins, selectins, and CD There are 40 ligands.
[0125] Despite recent advances, the terms "exosomes" and "microvesicles" have not been widely used in the literature. In this specification, the term "extracellular vesicles" refers to both The term is used to refer to either vesicle type.
[0126] The methods described herein involve screening a subject for the presence of a pathological prion-like protein. The method includes assaying a sample of extracellular vesicles.
[0127] The assays used to detect pathological prion-like proteins are suitable for such detection. The vector may be of any type known to those skilled in the art, including, but not limited to, a pathogenic prion. Assays used to detect prion-like proteins include, for example, By measuring the rate of aggregation over time, or by measuring the amount of aggregated prion-like proteins in a sample, by determining the presence or amount of protein The assay can detect the aggregation of prion-like proteins (e.g., By measuring the aggregation rate of prion-like proteins over time, or by measuring the amount of aggregated prion-like proteins in a sample, Pathological prion-like proteins detected (by determining the presence or amount of The protein may be compared to a reference level, which may be obtained from a control sample. The control sample or the predetermined reference level may be a control sample or a predetermined reference level. The test is a positive control or a predefined positive reference (to confirm that the method is working). level (negative control or pathological level above / above a predefined negative reference level) Any positive signal or detection of prion-like protein indicates disease progression in the subject's EV sample. a negative control or a predefined negative reference level (such as indicating the presence of a target prion-like protein) This is also possible. These include, but are not limited to, immunoEM, RT-QuIC, and PMCA. A variety of suitable assay types are known to those skilled in the art, including those described herein. Detailed methodology for this is provided in Fairfoul et al., 2016 and Ata Rashi et al., 2011 (for RT-QuIC); and Herva et al.,2014, Gonzalez-Montalban et al.,2 011, and Salvadore et al., 2014 (for PMCA) As can be seen, this is well established in the art. In a specific example, the RT-QuIC method of Fairfoul et al. (2016) to detect the presence of pathological prion-like proteins in EV samples as described herein. In particular, EV samples (CSF, brain tissue homogenates, plasma, serum, platelets, The pathological antigens in EV samples obtained from biological samples selected from buffy coats are Assay for the presence of lupus-synuclein.
[0128] The above assays (as well as in particular the RT-QuIC method described in the above-referenced paper) and PMCA) to identify pathological proteins other than alpha-synuclein in the EV samples of interest. Determine the presence of On-like proteins to identify the corresponding protein misfolding neurodegeneration The disorder (i.e., the presence of the pathological prion-like protein being measured and the corresponding protein mismatch) The aim of the study is to identify, monitor, and assess the risk of developing idiopathic neurodegenerative disorders (ADDs) such as idiopathic neurodegenerative disorders (ADDs) caused by ... Different pathological prion-like proteins (and their corresponding proteins) may be Examples of misfolding neurodegenerative disorders (ADs) have been described in detail above.
[0129] Therefore, they are suspected of suffering from a protein misfolding neurodegenerative disorder. or in a subject at high risk of developing a protein misfolding neurodegenerative disorder, Also provided is an in vitro method for determining the presence of a pathological prion-like protein, the method comprising: The process includes: (a) providing an extracellular vesicle sample from a subject; and (b) determining the presence of a pathological prion-like protein in the extracellular vesicle sample.
[0130] The presence of a pathological prion-like protein can be determined using any of the assays described in detail above. This can be used to make a judgment.
[0131] Extracellular vesicle samples were prepared or isolated using one of the methods previously described in detail. You can get it.
[0132] The permutations or combinations of suitable objects, terminology, and features have been described in detail above. .
[0133] Also provided is a method of selecting a treatment for a subject with a disease, the method comprising: determining the presence of a pathological prion-like protein in the exovesicle sample; The presence of a phosphokinin-like protein is indicative of a treatment for a protein misfolding neurodegenerative disorder in a subject. This indicates that the company will benefit from
[0134] The method may be an in vitro method.
[0135] The presence of a pathological prion-like protein can be determined using any of the assays described in detail above. This can be used to make a judgment.
[0136] Extracellular vesicle samples were prepared or isolated using one of the methods previously described in detail. You can get it.
[0137] The permutations or combinations of suitable objects, terminology, and features have been described in detail above. .
[0138] The method further comprises determining whether a pathological prion-like protein is present in an EV sample from the subject. If so, administering to the subject a treatment for the protein misfolding neurodegenerative disorder. That's fine.
[0139] The type of treatment depends on the specific pathological prion-like protein present (and therefore the corresponding That is, the subject is afflicted with, suspected of afflicting, at risk of developing, or has Depending on the risk of developing a protein misfolding neurodegenerative disorder This will change.
[0140] For example, a pathological alpha-synuclein protein is determined to be present and the subject is , alpha-synucleinopathies, e.g., Parkinson's disease, dementia with Lewy bodies, or Have, are suspected of having, are at risk of having, or are a known risk factor for multiple system atrophy If a patient is suspected of having a DLB disorder, the patient may be treated with, for example, a cholinesterase inhibitor ( ); may benefit from treatment with levodopa (for PD). The method includes administering a cholinesterase inhibitor (for DLB); levodopa (for PD); This may include the step of administering to a subject.
[0141] As a further example, a pathological prion-like protein is determined to be present and the subject is If you have, are suspected of having, or are at risk of having Leutzfeldt-Jakob disease, If the subject is suspected of being at risk for developing or having a condition, the subject may be treated with a compound that alleviates the symptoms indicated. The patient may benefit from treatment / treatment that alleviates the symptoms exhibited. The method may include administering a suitable therapeutic compound to the subject. Suitable compounds will be readily available to those skilled in the art. knowledge, and depends on the concrete symptoms of the subject.
[0142] As a further example, a pathological amyloid beta protein is determined to be present, and a subject has, is suspected of having, is at risk for, or is at increased risk of Alzheimer's disease If a subject is suspected of being at risk for developing a cholinesterase inhibitor, the subject may be Thus, the method is directed to a cholinesterase inhibitor. The method may include a step of administering.
[0143] As a further example, pathological tau protein is determined to be present and the subject is diagnosed with tauopaemia. Qi (e.g., Alzheimer's disease, frontotemporal lobar degeneration, progressive supranuclear palsy, or cortical base have, are suspected of having, are at risk of having, or are at risk of having If a patient is suspected of having a disease, the subject may be administered a compound / regimen (e.g., an anti-inflammatory drug) that alleviates the symptoms indicated. Depressants or selective serotonin reuptake inhibitors (to treat behavioral symptoms), cholinesterases inhibitors (to improve mental performance), or levodopa (for movement-related disease symptoms) )) can benefit from treatment with these appropriate The method may include administering any one or more of the treatments to the subject. Other suitable treatments are known in the art. Treatment options are well known to those skilled in the art and depend on the specific symptoms of the subject.
[0144] As a further example, a pathological huntingtin protein is determined to be present and the subject is Are you suffering from, suspected of having, at risk of having, or at risk of suffering from Huntington's disease? If a patient is suspected of having a pulmonary bypass graft, the patient may be administered a compound / regimen (e.g., Appropriate treatment includes medications to reduce movement disorders (e.g., tetrabenazine); Patients may benefit from treatment with antidepressants, antipsychotics, and mood stabilizers that help relieve symptoms. Thus, the method includes administering to the subject any one or more of the suitable treatments described above. Other suitable treatments will be known to those of skill in the art and will depend on the subject's particular condition. It is decided.
[0145] Further examples include pathological superoxide dismutase, c9orf72, or valproate. There are prion proteins and other prion-like proteins associated with motor neuron diseases. and the subject is determined to have or be suspected of having a motor neuron disease. If the subject is at risk or suspected of being at risk for the condition, the subject may be administered a treatment to alleviate the symptoms exhibited. Compounds / regimens that counteract this (e.g., riluzole and radicava (FDA-approved drugs); from treatment with other medications that alleviate symptoms (e.g., antidepressants, nonsteroidal anti-inflammatory drugs). Thus, the method may include one or more of the appropriate treatments described above. Other suitable treatments will be known to those of skill in the art and may include administering to the subject It depends on the specific symptoms.
[0146] As a further example, a pathological atrophin protein is determined to be present and the subject is Lis who have, are suspected of having, or are suffering from Dentatopalidol Broiler-Luisian Atrophy If the subject is suspected of having or being at risk of having a disease, the subject may be administered a compound that alleviates the symptoms indicated. Benefit from treatment with a drug / regimen (e.g., antiepileptic, psychotropic, or riluzole) Thus, the method may include one or more of the appropriate treatments described above. Other suitable treatments will be known to those of skill in the art and may include administering to the subject a It depends on the physical symptoms.
[0147] Further examples include pathological ataxin proteins (ataxin-1, ataxin-2, ataxin-3, ataxin-4, ataxin-5, ataxin-6, ataxin-7, ataxin-8, ataxin-9, ataxin-10, ataxin-11, ataxin-12, ataxin-13, ataxin-14, ataxin-15, ataxin-16, ataxin-17, ataxin-18, and determining that the subject is suffering from spinocerebellar ataxia. If a subject is suspected of having, is at risk of having, or is suspected of being at risk of having , to a compound / regimen that alleviates the symptoms indicated (e.g., physical therapy, or riluzole). The method may therefore include any one of the suitable treatments described above. Other suitable procedures will be known to those of skill in the art, and may include administering one or more of the following to a subject: It depends on the specific symptoms of the subject.
[0148] Also, the present invention relates to identifying or monitoring a protein misfolding neurodegenerative disorder in a subject. or for determining the risk of developing a protein misfolding neurodegenerative disorder in a subject Use of an in vitro extracellular vesicle sample to determine the presence or absence of a marker for a cancer is provided.
[0149] The permutations or combinations of suitable objects, terminology, and features have been described in detail above. .
[0150] The present invention also aims to determine the therapeutic efficacy of treatment regimens for protein misfolding neurodegenerative disorders. An in vitro method for determining whether a nucleic acid sequence is a nucleotide sequence is provided, the method comprising the steps of: a) Assaying extracellular vesicle samples from subjects for the presence of pathological prion-like proteins. The process of making; b) performing step a) for a period of time using an extracellular vesicle sample obtained from the subject after the treatment. repeating for a time interval; and c) determining the level of the pathological prion-like protein in step a) in step b); The levels of pathological prion-like protein were reduced after treatment compared to the levels determined in the control group. If so, confirming that the treatment regimen is therapeutic.
[0151] Suitable objects, procedures, terminology, and permutations or combinations of features are described in detail above. It has come.
[0152] Also provided are methods for treating a given treatment regimen for a protein misfolding neurodegenerative disorder. In vitro methods for determining compliance or adherence to the method are provided, The method includes the steps of: a) Assaying extracellular vesicle samples from subjects for the presence of pathological prion-like proteins. The process of making; b) using an extracellular vesicle sample obtained from the subject after a given initiation of the treatment regimen; repeating step a); and c) determining the level of the pathological prion-like protein in step a) in step b); The levels of pathological prion-like protein were reduced after treatment compared to the levels determined in the control group. If so, confirming that the subject has been compliant or adherent to the prescribed treatment regimen.
[0153] Suitable objects, procedures, terminology, and permutations or combinations of features are described in detail above. It has come.
[0154] We also demonstrated that EVs obtained from CSF samples of PD or DLB patients The data confirmed that the patient's EVs showed significant lipid changes compared to controls. This suggests that significant lipid changes are important in the pathology. The lipid changes are in accordance with the methods of detecting pathological alpha-synuclein described herein. This may be part of the high sensitivity and specificity of the The in-aggregation assay responded to both modifications (ceramide and synuclein folding). The change in ceramide in pathological conditions is very important, and the brain tissue of patients These changes are similar to those observed in patients with PD and DLB (data not shown). Advantageously, the changes in lipid composition may be more relevant, especially in the context of alpha-synucleinopathy. Specifically with respect to PD and / or DLB, to detect disease (or risk of disease); It can be used as a biomarker for monitoring and identification.
[0155] Thus, in vitro methods for identifying or monitoring alpha synucleinopathy in a subject are disclosed. A method is provided, the method comprising the steps of: a) Cer 32:1, Cer 33:1, and Cer 34:1 in the target extracellular vesicle sample. 34:1, Cer 34:2, Cer 37:1, Cer 38:1, Cer 38:2 ,Cer 39:1,Cer 39:2,Cer 40:1,Cer 40:2,Cer 41:1, Cer 41:2, Cer 40:1(OH), and Cer 40:2( OH); And b) assessing the amount of at least one ceramide species by measuring the amount of at least one ceramide species; comparing with a reference value; wherein at least one ceramide species is greater than a reference value for at least one ceramide species. The assessment of ceramide species is indicative of alpha synucleinopathy.
[0156] Also, an in vitro method for determining a subject's risk of developing alpha synucleinopathy. is provided, comprising the steps of: a) Cer 32:1, Cer 33:1, and Cer 34:1 in the target extracellular vesicle sample. 34:1, Cer 34:2, Cer 37:1, Cer 38:1, Cer 38:2 ,Cer 39:1,Cer 39:2,Cer 40:1,Cer 40:2,Cer 41:1, Cer 41:2, Cer 40:1(OH), and Cer 40:2( assessing the amount of at least one ceramide species selected from the group consisting of: b) assessing the amount of at least one ceramide species by measuring the amount of at least one ceramide species; comparing with a reference value; wherein at least one ceramide species is greater than a reference value for at least one ceramide species. The assessed amount of ceramide species indicates that the subject is at high risk of developing alpha-synucleinopathy. Shows.
[0157] As described elsewhere herein, alpha synucleinopathies include Parkinson's disease (including Parkinson's disease dementia), dementia with Lewy bodies, and multiple system atrophy In particular, the alpha synucleinopathy may be selected from the group consisting of Parkinson's disease, or dementia with Lewy bodies.
[0158] As described elsewhere herein, the method further comprises the steps of: Or even: i) providing a biological sample from a subject; and ii) Isolating extracellular vesicle samples from biological samples using size exclusion chromatography The process of obtaining the above.
[0159] Suitable subjects, extracellular vesicle samples, biological samples, methods for obtaining extracellular vesicle samples, specialized The terminology and combinations or permutations of features are described elsewhere in this specification and are not intended to be limiting. This applies equally to the ceramide embodiments described herein.
[0160] Suitable methods for assessing the amount of at least one of the above ceramide species are known in the art. As a non-limiting example, the method used in the Examples section below is Examples include the high-resolution Thermo Orbitrap Exac Use the tive system in positive and negative ion modes ( For example, using a C18 column and a HILIC column), liquid chromatography mass spectrometry Analysis (LC-MS). Other suitable methods will be known to those skilled in the art.
[0161] The estimated amount of at least one ceramide species is compared to a reference value for that ceramide species. For example, the amount of Cer 32:1 and Cer 33:1 in step a) of the method If the amount of Cer 32:1 from step a) is evaluated by the method, step b) of the method further comprises: and comparing the amount of Cer 33:1 from step a) with the reference value for Cer 32:1. , comparing with a reference value for Cer 33:1, etc.
[0162] The method further comprises the steps of: during the comparison step (step b)), comparing the evaluated quantity in step a) with a corresponding reference value is indicative of alpha synucleinopathy in the subject.
[0163] The method includes the step of: At least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least At least 10, at least 11, at least 12, at least 13, at least 14 species, Alternatively, the amounts of all 15 may be evaluated.
[0164] Multiple ceramide species may be evaluated within the method. In this example, the ceramides tested were The amount of at least one (and possibly all) of the species is greater than or equal to the reference amount for these ceramide species. If the value is greater than this, the patient is diagnosed with alpha synucleinopathy (or the patient is alpha synucleinopathic). For example, at least one of the above ceramide species, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7 , at least 8, at least 9, at least 10, at least 11, at least 12, a few The amounts of at least 13, at least 14, or all 15 of these ceramide species were If the α-synucleinopathy is greater than the reference value, the patient is diagnosed with alpha synucleinopathy (or the patient is alpha synucleinopathy). (high risk of developing craynopathies).
[0165] The reference value may be obtained from a control sample or may be a predetermined reference value.
[0166] As used herein, a "control sample" refers to a sample that is free of pathological prion-like proteins. For example, those not suffering from or suffering from a protein misfolding neurodegenerative disorder Samples from healthy subjects not suspected of having Samples from the same subjects as those being examined, e.g., those with any clinical symptoms or protein mutations The term refers to a sample obtained prior to a risk factor for developing a neurodegenerative disorder. Other suitable control samples can be readily identified by one of skill in the art.
[0167] As used herein, a "predetermined reference value" refers to a reference that may be constructed from a reference database. It refers to a level (which may be used to generate a predetermined cut-off value), i.e. The score may be a diagnostic score that statistically predicts a condition or disease, or the lack thereof, or may be a standard A pre-defined reference level may be based on a general population sample, or alternatively, a baseline The reference level may be a predetermined level based on baseline expression levels, i.e., Clinical symptoms or risk factors for developing protein misfolding neurodegenerative disorders Appropriate predetermined reference values can be readily identified by one of ordinary skill in the art.
[0168] Suitable subjects, extracellular vesicle samples, biological samples, methods for obtaining extracellular vesicle samples, Methods for assessing the amount of ceramide species, combinations of ceramide species for analysis, reference levels, terminology and combinations or permutations of features are described elsewhere herein and are not intended to be limiting. The same applies to the above aspects.
[0169] Also, if you are suspected of having alpha-synucleinopathy or have alpha-synuclein In subjects at high risk of developing inopathies, Cer 32:1, Cer 33:1, and C er 34:1, Cer 34:2, Cer 37:1, Cer 38:1, Cer 38 :2, Cer 39:1, Cer 39:2, Cer 40:1, Cer 40:2, C Cer 41:1, Cer 41:2, Cer 40:1(OH), and Cer 40: 2(OH) A Toro method is provided, the method comprising the steps of: (a) providing an extracellular vesicle sample from a subject; and (b) Cer 32:1, Cer 33:1, and Cer 34 in extracellular vesicle samples. :1, Cer 34:2, Cer 37:1, Cer 38:1, Cer 38:2, C er 39:1, Cer 39:2, Cer 40:1, Cer 40:2, Cer 4 1:1, Cer 41:2, Cer 40:1(OH), and Cer 40:2(OH ).
[0170] The amount of at least one ceramide species can be determined using any of the assays described in detail above. can be obtained by:
[0171] Extracellular vesicle samples were prepared or isolated using one of the methods previously described in detail. You can get it.
[0172] The permutations or combinations of suitable objects, terminology, and features have been described in detail above. .
[0173] Also provided is a method of selecting a treatment for a subject with a disease, the method comprising the steps of: Process includes: a) Cer 32:1, Cer 33:1, and Cer 34:1 in the target extracellular vesicle sample. 34:1, Cer 34:2, Cer 37:1, Cer 38:1, Cer 38:2 ,Cer 39:1,Cer 39:2,Cer 40:1,Cer 40:2,Cer 41:1, Cer 41:2, Cer 40:1(OH), and Cer 40:2( assessing the amount of at least one ceramide species selected from the group consisting of: b) assessing the amount of at least one ceramide species by measuring the amount of at least one ceramide species; comparing with a reference value; wherein at least one ceramide species is greater than a reference value for at least one ceramide species. 2. Assessing the amount of ceramide species that a subject will benefit from a treatment for alpha synucleinopathy It is shown that
[0174] The method may be an in vitro method.
[0175] The amount of at least one ceramide species can be determined using any of the assays described in detail above. can be obtained by:
[0176] Extracellular vesicle samples were prepared or isolated using one of the methods previously described in detail. You can get it.
[0177] The permutations or combinations of suitable objects, terminology, and features have been described in detail above. .
[0178] The method further comprises determining an amount of at least one ceramide species in an EV sample from a subject, the amount being: If the value is greater than the reference value for at least one ceramide species, alpha-synucleinoside The method may include administering to the subject a treatment for the pathology.
[0179] For example, a pathological alpha-synuclein protein is determined to be present and the subject is , alpha-synucleinopathies, e.g., Parkinson's disease, dementia with Lewy bodies, and Have, are suspected of having, are at risk of having, or are a known risk factor for multiple system atrophy If a patient is suspected of having a cholinesterase inhibitor (for DLB) or may benefit from treatment with levodopa (for PD). Methods include cholinesterase inhibitors (for DLB) or levodopa (for PD) The method may include administering to a subject.
[0180] Suitable subjects, extracellular vesicle samples, biological samples, methods for obtaining extracellular vesicle samples, specialized The terminology and combinations or permutations of features are described elsewhere in this specification and are not intended to be limiting. This applies equally to the ceramide embodiments described herein.
[0181] Also, for identifying or monitoring alpha synucleinopathy in a subject, or Cer 32 for determining the risk of developing alpha synucleinopathy in a subject :1, Cer 33:1, Cer 34:1, Cer 34:2, Cer 37:1, Ce r 38:1, Cer 38:2, Cer 39:1, Cer 39:2, Cer 40 :1, Cer 40:2, Cer 41:1, Cer 41:2, Cer 40:1(O H), and Cer 40:2(OH), Uses of exovesicle ceramide species are provided.
[0182] The permutations or combinations of suitable objects, terminology, and features have been described in detail above. .
[0183] In addition, in vitro assays to assess the therapeutic efficacy of treatment regimens for alpha synucleinopathy are also used. A method is provided, the method comprising the steps of: a) Cer 32:1, Cer 33:1, and Cer 34:1 in the target extracellular vesicle sample. 34:1, Cer 34:2, Cer 37:1, Cer 38:1, Cer 38:2 ,Cer 39:1,Cer 39:2,Cer 40:1,Cer 40:2,Cer 41:1, Cer 41:2, Cer 40:1(OH), and Cer 40:2( assessing the amount of at least one ceramide species selected from the group consisting of: b) performing step a) for a period of time using an extracellular vesicle sample obtained from the subject after the treatment. repeating at intervals; and c) measuring the amount of at least one ceramide species determined in step a) in step b); If the amount of at least one ceramide species is decreased after treatment compared to the amount determined by confirming that the treatment regimen is therapeutically effective.
[0184] Suitable objects, procedures, terminology, and permutations or combinations of features are described in detail above. It has come.
[0185] Also, the subject's compliance or adherence to a prescribed treatment regimen for alpha synucleinopathy. An in vitro method for determining whether a patient is a candidate for a pulmonary circulation disorder is provided, the method comprising the steps of: a) Cer 32:1, Cer 33:1, and Cer 34:1 in the target extracellular vesicle sample. 34:1, Cer 34:2, Cer 37:1, Cer 38:1, Cer 38:2 ,Cer 39:1,Cer 39:2,Cer 40:1,Cer 40:2,Cer 41:1, Cer 41:2, Cer 40:1(OH), and Cer 40:2( assessing the amount of at least one ceramide species selected from the group consisting of: b) using an extracellular vesicle sample obtained from the subject after a given initiation of the treatment regimen; repeating step a); and c) measuring the amount of at least one ceramide species determined in step a) in step b); If the amount of at least one ceramide species is decreased after treatment compared to the amount determined by , confirming that the subject has complied or adhered to the prescribed treatment regimen.
[0186] Suitable objects, procedures, terminology, and permutations or combinations of features are described in detail above. It has come. EXAMPLES
[0187] The data presented here demonstrate that the use of extracellular vesicles in combination with the RTQUIC method Thus, demonstrating increased sensitivity of the method in detecting pathological protein aggregation.
[0188] Using routine RTQUIC assays, we have demonstrated that RTQUIC assays can be used to detect cerebrospinal fluid, plasma, and We tested extracellular vesicles purified from IgG and platelets to detect alpha-synuclein pathology. The sensitivity of the assay when using pure (unpurified) specimens is significantly increased compared to the use of pure (unpurified) specimens. Initial analysis 15 postmortem cerebrospinal fluid samples (11 diagnosed with Parkinson's disease + Lewy body dementia) cranium), and 4 controls. All cases were clinically and neuropathologically verified. Ta.
[0189] Extracellular vesicles were purified from all cases using size exclusion chromatography. The vesicles were then subjected to a tunable resistive pulse to determine their size and concentration (Figures 1 and 2). sensing (TRPS) and in the presence of accepted markers (Figure 3). The results were analyzed by Western blot and immunoelectron microscopy.
[0190] Next, the inventors used immunoelectron microscopy to confirm the presence of alpha-synuclein. All samples were screened for alpha-synuclein associated with the vesicle membrane. The presence of synuclein was detected in patient samples. and control samples. One PD sample had alpha-synuclein Alpha-synuclein was expressed in larger vesicles (average diameter 22 mm). Although the alpha-synuclein labeling appeared to be associated with membranes of 1 nm or less, the internal alpha-synuclein labeling was more This observation was characteristic of smaller vesicles (mean diameter 122 nm) (Figures 4 and 5). , were characteristic of vesicles from patients and controls.
[0191] The present inventors have used liquid chromatography using a C18 column and a HILIC column. - Mass spectrometry (LC-MS) in positive and negative ion modes We performed a comprehensive lipidomic analysis of all vesicles from PD and DLB patients using Significant changes in the abundance of ceramide species in vesicles were identified compared to control vesicles (Figure 6 and Figure 7).
[0192] Without being bound to any particular theory, one explanation for these data is that the EV It is not simply alpha-synuclein that changes, but rather the components of the EV themselves that change. and changes in composition can affect how the RTQUIC assay responds and / or One study found that alpha-synuclein in EVs changes.
[0193] A study of extracellular vesicles purified from frontal cortex brain tissue. We used a method that was extensively modified by Perez-Gonzalez (2012). EVs were purified from brain tissue using the protocol. Quality check analysis was performed as previously described for CSF. Follow the EVTRPS procedure to verify vesicle purity, concentration, and size, i.e. and transmission electron microscopy (Figure 8). Vesicle markers were detected by Western blot analysis. The absence of calnexin was determined by blotting (Figures 9 and 10). The inventors have demonstrated the high purity and lack of contamination by cellular material in several The morphology of vesicle proteins, i.e. synaptophysin and snap25, and their attachment to vesicles The small amount of mitochondrial protein TFAM (mitochondrial receptor agonist (TFAM)) that is thought to be associated with mitochondrial (Note the absence of porin, a mitochondrial membrane marker, proving the absence of the entire Immunoelectron microscopy was used to determine the location (intravesicular or associated) relative to EVs. The inventors have demonstrated that alpha-synuclein in the vesicular fraction is increased in patients and controls. Lein was detected and quantified using ELISA (Figure 11). No significant changes in acetylcholine levels were detected.
[0194] RTQUIC The RTQUIC assay was performed using purified CSF vesicles and unprocessed CSF. When purified vesicles were used, the assay demonstrated 100% sensitivity and 10 0% specificity. Furthermore, it detected prodromal symptoms of the disease (clinically, Parkinson's disease). Controls without symptoms or memory impairment. However, mild neuropathological changes can be seen in the brain, which Over time, it has been suggested that the disease may progress to clinically evident disease. The RTQUIC protocol published at oul 2016. The positive control for the assay is shown in Figure 1. Shown in 3.
[0195] Ongoing research into blood vesicles Previous studies using RTQUIC have demonstrated that unprocessed plasma, platelets, or No alpha-synuclein pathology was detected when buffy coat was used ( We now demonstrate that RT-PCR is a novel method to detect EVs derived from plasma and platelets. Representative data are shown in Figures 14 and 15. The use of cells has significantly improved detection of disease signals. Using this method, the inventors have identified positive signals from samples that may be preclinical symptoms of disease. The signal can be detected.
[0196] Further examples (see Figures 16 to 22): Six samples of postmortem CSF from individuals with the following clinical and neuropathological diagnoses: The following diseases were tested: Parkinson's disease (PD, 1 sample), dementia with Lewy bodies (DLB, 3 samples) and healthy controls (2 samples). Also, Parkinson's disease brain homogenates, As well as extracellular vesicles isolated from the frontal cortex of DLB and controls were examined.
[0197] In addition, multiple system atrophy (MSA), corticobasal syndrome (CBS), progressive supranuclear palsy (PSP) SP, Steele-Richardson-Olszewski syndrome), or healthy Seven urine samples from either control or clinically diagnosed individuals were tested.
[0198] Human urine samples using SEC and human postmortem CSF samples using ultracentrifugation From the cells, extracellular vesicles were successfully purified, as confirmed by transmission electron microscopy (Figure 16). and Figure 17).
[0199] The results of the protein aggregation assay were as follows: 1 Postmortem CSF samples - Lewy body pathology in all 4 replicates analyzed per sample 100% specificity in detecting (Figure 18, Figure 19, and Figure 20). 2 Urine samples - Samples were analyzed blinded to disease status (Figures 21 and 22). The results showed that we were able to clearly distinguish cases of MSA in both replicates. This shows that:
[0200] material and method: Purification of extracellular vesicles from postmortem CSF and plasma: Frozen CSF, plasma, and platelets were thawed on ice, vortexed vigorously, and then Anything that may have adhered to the walls of the tube was put back into solution. CSF and plasma were Preclear by centrifugation; CSF 1500g, 3000g, and 10 1,000g, 10 min each step; plasma 1500g, 3000g, 3000g, 10 min each step .
[0201] If more than 500 μl of material is available, samples are concentrated using a VivaSpin centrifuge. The eluate can be concentrated to 500 μl using a Sartorius condenser. 0 μl of the sample is loaded onto a size exclusion chromatography (SEC) column. In their study, the inventors used a qEV (Izon) standard 500 μl SEC column. CSF / plasma was loaded onto the column and fractions were eluted with PBS. According to this, the first 6 × 500 μl fractions (collected for a total of 3 ml fractions) were The vesicles are contained in fractions 7, 8, and 9. All three fractions were combined into one tube. The supernatant was collected in a tube and diluted to 500 μl using a VivaSpin 2 (Sartorius). The concentrated vesicles were stored at -80°C in aliquots to avoid freeze-thaw cycles. It remained.
[0202] Purification of frozen frontal cortex extracellular vesicles Extracellular vesicles were modified significantly from Perez-Gonzalez et al. 2012. The tissue was purified from frozen tissue according to the protocol described in the literature. A minimum of 600 mg of frozen frontal cortex was used. The tissue was thawed on ice and dissected. Hibernate supplemented with papain (Sigma, final concentration 20 units / ml) The solution was dissolved in E (Gibco, ThermoFisher) at 37°C for 15 min with shaking. Hibernate containing a protease inhibitor cocktail (Roche) Add E to a total volume of 10 ml and pass through a 10 ml serological pipette. The tissue was then gently homogenized. The dissociated tissue was passed through a 40 μm mesh filter. The filtrate was filtered using a centrifuge at 300g for 10 minutes, 2000g for 10 minutes, and then 10,0 The mixture was centrifuged at 1000g for 30 min. The supernatant was collected at each step. The final supernatant was diluted with 0.45 μl of ethanol. 500 ml filter and then centrifuged in a VivaSpin Turbo 4 centrifugal concentrator. The sample was concentrated to 500 μl using a SEC column (Sartorius). Applied to EV column and processed as for CSF EVs for EV isolation. .
[0203] TRPS is provided by Izon Science.
[0204] Electron microscopy 5 μl of the vesicle suspension in PBS was applied to a glow-discharged carbon-coated copper grid for a few seconds. The grids were dried by touching them to filter paper and stained with 2% uranyl acetate. The grids were stained for 100 s. The grids were then dried. The grids were then stained for 100 s ... The digital images were then examined using a 3D TEM (FEI) transmission electron microscope. Acquisition was performed using an AMT CCD camera (Deben).
[0205] Western blot 18 μl of exosome extract was diluted with Invitrogen according to the manufacturer's instructions. NuPAGE 4-12% Bis-Tris gel electrophoresis system was used to The CD63 and CD81 were examined under non-reducing conditions. All antibodies were purchased from Abcam, but Alix (Cell Signalling) and and SNAP25 (Sigma). Antibodies were incubated with the membrane overnight at 4°C, followed by Incubate with appropriate secondary antibodies (Dako) for 1 hour at room temperature and then use Pierce EC L Plus Western Blotting Substrate or SuperSignal West Using Femto Maximum Sensitivity Substrate Signals were detected with an Amersham Imager 600.
[0206] Lipidomics EV lipids were extracted in chloroform / methanol (2 / 1, v / v). High-resolution Thermo Orbitrap Ex using HPLC and HILIC columns The active system was used in positive and negative ion modes. To perform comprehensive (non-targeted) lipidomic analysis, we used liquid chromatography-mass spectrometry (LC-MS) The data set was analyzed using the Non-Linear Dynamics Processing (alignment, deconvolution) was performed using Progenesis QI software. The data were analyzed using SIMCA-P software. The set was subjected to multivariate data analysis (principal component analysis (PCA) and orthogonal partial least squares - discriminant analysis) By subjecting the subjects to OPLS-DA, the disturbance (relative change) in the lipid profile was determined. Lipids were identified using LIPID MAPS (www.lipidmaps.org / ), by searching the HMDB (http: / / www.hmdb.ca / ) database. Lipid classes were identified by comparison to internal standards that were representative of the major lipid classes. Statistical analysis included the Shapiro-Wilk normality test according to the data set. Tests followed by one-way anova, unpaired t-tests, or nonparametric tests Included.
[0207] ImmunoEM This was performed in the EM facility at St Andrews University.
[0208] The vesicles were bound to the support and incubated with an anti-alpha-synuclein antibody (BD Transducer tion Laboratories) and then labeled with electron-dense gold particle markers. The vesicles were then contrasted with heavy metals in a thin film of methylcellulose. Then, they were imaged by electron microscopy.
[0209] Alpha-Synuclein ELISA The ELISA plate was incubated with anti-alpha-synuclein 10D2 antibody (Analitik Jena, 1:2000) (Coating Buffer (Carbonate-Bicarbonate Buffer: 50mM 1 ml of 0.2 M sodium bicarbonate + 5 ml of 0.2 M sodium carbonate) The wells were coated overnight at 4° C. in a total volume of 100 μl. The plates were washed three times with water + 0.2% Tween (PBST). Blocked with 200 μl of 1% BSA in T and agitated on a rocking plate for 1 hour. Afterwards, the mixture was washed once with PBST. Recombinant alpha-synuclein standard (Sigma-Aldrich) ldrich; 40 - 0.001ng / μl) and the samples were diluted in PBS + 0.2% Tween Prepare the plates in 200 mL of 100 mL of 100% ethanol and load 100 μl per well. The wells were washed three times with PBST. The detection antibody αβ-synuclein (Abca m, 1:1500) (in 1% BSA in PBST) was added (100 μl per well). The mixture was agitated on a rocking plate for 1 hour and then washed three times with PBST. Goat anti-rabbit AP (Santa Cruz, 1:1000) (in 1% BSA in PBST) Add 100 μl of each of the following per well and mix on a rocking plate for 1 hour. Then, the cells were washed three times in PBST. pNPP (p-nitrophenyl phosphate; Sigma) a-Aldrich) substrate was dissolved in substrate buffer (0.05M sodium carbonate + 0.001 MgCl2 (in dH2O) at 1 mg / ml, and 100 μl per well The plate was incubated at 37°C for 30 minutes and the absorbance was measured at 412 nm. This was recorded.
[0210] RTQUIC RTQUIC was previously published in Fairfoul at al. 2016. It was carried out as follows.
[0211] Further Materials and Methods (see Figures 16-22): Purification of extracellular vesicles from postmortem cerebrospinal fluid samples using ultracentrifugation.
[0212] Thaw frozen postmortem cerebrospinal fluid (CSF) samples (1 ml–1.5 ml) on ice. , vortex vigorously, and freeze at 500 × g for 10 min and 2,000 × g for 15 min at 4 °C. The cells were precleared by centrifugation at 17,000×g for 30 min ( The supernatant was centrifuged each time.) A TLA 55 S / N 17U1340 rotor was used. Optima Max-XP Ultracentrifuge Beckman The final supernatant was ultracentrifuged at 130,000 × g for 1 hour at 4°C in a Coulter. The supernatant was discarded and the pellet was washed with phosphate buffered saline (PBS) for 130 min. The supernatant was discarded and the pellet was centrifuged again at 4,000×g for 1 hour at 4° C. The samples were resuspended in PBS containing a protease inhibitor cocktail (Roche). The cells were negatively stained and imaged using a Hitachi HT7800 120 kV electron microscope. The images were taken using transmission electron microscopy with a TEM imager.
[0213] Purification of extracellular vesicles from human urine samples. Thaw a frozen urine sample (35-100 ml) and vortex vigorously. 1500×g for 10 min, 3000×g for 10 min, and 4600×g for 10 min at 4°C. The supernatant was precleared by centrifugation at 4°C for 30 min (the supernatant was centrifuged each time). The final supernatant was filtered through an Amicon ultrafiltration unit with a molecular weight cut-off of 100 kDa (M The filtrate was concentrated to 500 μl using a 1610 Millipore The supernatant was centrifuged at 0 × g for 10 min at 4°C and purified using qEVO according to the manufacturer's recommendations. Size exclusion chromatography using an original 70 nm SEC column (Izon) The vesicle fraction of 1500 μl was collected and subjected to SEC with a molecular weight cutoff of 3 kDa. Concentration was performed using a micon ultrafiltration unit (Merck Millipore). Samples were negatively stained and analyzed using a Hitachi HT7800 120 kV electron microscope. The images were taken using transmission electron microscopy.
[0214] Alpha-synuclein protein aggregation assay. Protein aggregation assays were performed as previously described in Fairfoul et al. (2016). The procedure was performed as described in the literature. The reaction was run using an ltimode plate reader and the fluorescent signal was measured for 1 h. Postmortem CSF samples were collected at 15-hour intervals, with two different amounts of vesicles. The data were analyzed twice with duplicates testing. Fisher) was used for analysis.
[0215] Unless otherwise defined herein, all technical and scientific terms used herein are Terms have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. For example, SINGLETON AND SAINSBURY, DICTIONAR Y OF MICROBIOLOGY AND MOLECULAR BIOLOGY, 2D ED., JOHN WILEY AND SONS, NY (1 94); and H ALE AND MARHAM,THE HARPER COLLINS DICTIO NARY OF BIOLOGY,HARPER PERENNIAL,NY(1991 ) provides one of ordinary skill in the art with a general dictionary of many of the terms used in this specification. Any methods and materials similar or equivalent to those described herein may be used in the practice of the present invention. Although various methods and materials are available, preferred methods and materials are described herein. The terms defined in are more fully described by reference to the entire specification. As used herein, the singular terms "A," "AN," and "THE" are used where the context requires. Plural references are included unless expressly indicated otherwise. Written from left to right in 5' to 3' orientation; amino acid sequences are written from left to right The present invention is directed to the specific methodology, process, and It should be understood that the present invention is not limited to the protocols and reagents used herein, as these may be readily understood by those of skill in the art. Therefore, it may vary depending on the context in which it is used.
[0216] The reader is advised to refer to any related application filed concurrently with or prior to this application, and to all articles and documents open to public inspection together with this specification, The contents of all articles and documents are incorporated herein by reference.
[0217] All of the information disclosed in this specification (including any accompanying claims, abstract, and drawings) is Every feature and / or step of any method or process disclosed therein. refers to combinations of at least some of such features and / or steps that are mutually exclusive. may be combined in any combination except for the above.
[0218] Each of the features disclosed in this specification (including any accompanying claims, abstract, and drawings) A feature may be replaced by an alternative feature serving the same, equivalent, or similar purpose, unless expressly stated otherwise. Thus, unless expressly stated otherwise, each feature disclosed is to be construed as a generic equivalent. is merely one example of a series of equivalent or similar features.
[0219] The invention is not limited to the details of any of the preceding embodiments. The present invention relates to a method for producing a method for the production of a compound according to the present invention. Any novel combination or method so disclosed is also The present invention extends to any novel invention or any novel combination of process steps.
[0220] Reference materials McKeith et al., Neurology. 2017 Jul 4;89(1):88-100. Diagnosis and management o f dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Postuma et al., Mov Disord. 2015 Oct;30(12):1591-601. MDS clinical diagnostic criteria for Parkinson's disease. Han-Joon Kim et al., Journal of Neurology, August 2015, Volume 262, Issue 8, pp 1801-1813; Diagnosis and differential diagnosis of MSA: boundary issues. Gallea et al., J Biol Chem. 2014 Sep 26; 289(39): 26733-42. Structural insight s into amyloid oligomers of the Parkinson disease-related protein α-synuclein. Tuttle et al., Nat Struct Mol Biol. 2016 May;23(5):409-15. Solid-state NMR str ucture of a pathogenic fibril of full-length human α-synuclein. Zerr et al., APMIS. 2002 Jan;110(1):88-98. Clinical diagnosis and differential diagnosis of CJD and vCJD. With special emphasis on laboratory tests. Gallagher-Jones et al., Nat Struct Mol Biol. 2018 Feb;25(2):131-134. Sub-angst rom cryo-EM structure of a prion protofibril reveals a polar clasp. Desai et al., Neurology. 2005 Jun 28;64(12 Suppl 3):S34-9.Diagnosis and treat ment of Alzheimer's disease. Schmidt M et al., Proc Natl Acad Sci U S A. 2015 Sep 22;112(38):11858-63. Pept ide dimer structure in an Aβ(1-42) fibril visualized with cryo-EM. Fitzpatrick et al., Nature. 2017 Jul 13;547(7662):185-190. Cryo-EM structures of tau filaments from Alzheimer's disease. Hoglinger GU et al., Mov Disord. 2017 Jun;32(6):853-864. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Salvadores et al., cell reports 7, 261-268, 2014. Detection of misfolded AB ol igomers for sensitive biochemical diagnosis of Alzheimer’s disease. Loov et al., cell Mol Neurobiol 2016. Alpha-synuclein in extracellular vesicle s; functional implications and diagnostic opportunities. Fairfoul et al., Annals of Clinical and translational neurology; 2016 (pp 812 - 818). Alpha-synuclein RT-QUIC in the CSF of patients with alpha-synucleinopath ies. Herva et al., the journal of biological chemistry vol 289 No 17 pp 11897-11905 , 2014. Anti-amyloid compounds inhibit alpha-synuclein aggregation induced by pr otein misfolding cyclic amplification (PMCA). Boing et al., journal of extracellular vesicles, 3:23430; 2014. Single-step is olation of extracellular vesicles by size-exclusion chromatography. Mollenhauer et al., lancet Neurol 2011; 10: 230-40. Alpha-synuclein and tau co ncentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Danzer et al., Molecular Neurodegeneration 2012, 7:42 Exosomal cell-to-cell tr ansmission of alpha synuclein oligomers. Luk et al., JAMA Neurol 2016: 73 (12): 1454-1460. Diagnosing sporadic Creutzfe ldt-Jakob disease by the detection of abnormal prion protein in patient urine. Lobb et al., journal of extracellular vesicles 2015, vol 4: 27031. Optimised e xosome isolation protocol for cell culture supernatant and human plasma. Andaloussi et al., Nature Reviews Drug Discovery, vol 12, May 2013, page 347-3 57. Extracellular vesicles; biology and emerging therapeutic opportunities. Atarashi et al., nature medicine vol 17 number 2, 2011. Ultrasensitive human p rion detection in cerebrospinal fluid by real-time quaking-induced conversion. Gonzalez-Montalban et al., Plos Pathogens vol 7, issue 2, 2011. Highly efficie nt protein misfolding cyclic amplification. Perez-Gonzalez et al. The journal of biological chemistry vol. 287 No51 pp 431 08-43115, 2012. The exosome secretory pathway transports amyloid precursor prote in carboxyl-terminal fragments from the cell into the brain extracellular space. Stuendl et al., Brain A journal of Neurology 2016; 139; 481-494 Induction of a lpha-synuclein aggregate formation by CSF exosomes from, patients with Parkinson ’s disease and dementia with Lewy bodies. McKhann et al. The diagnosis of dementia due to Alzheimer's disease: recommend ations from the National Institute on Aging-Alzheimer's Association workgroups o n diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7: 263 -269 Dubois et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014; 13: 614-629. Isas et al., Biochemistry. 2017 Jul 18;56(28):3579-3586. Pagan F, et al., Handb Clin Neurol. 2017;144:63-67. Traynor et al., Clinical features of amyotrophic lateral sclerosis according t o the El Escorial and Airlie House diagnostic criteria: A population-based study . Arch Neurol 2000;57:1171-1176. Wardle et al., Mov Disord. 2009 Aug 15;24(11):1636-40. van de Warrenburg et al., EFNS / ENS Consensus on the diagnosis and management o f chronic ataxias in adulthood. Eur J Neurol. 2014 Apr;21(4):552-62. Sangwan S et al., Proc Natl Acad Sci U S A. 2017 Aug 15;114(33):8770-8775. Ato mic structure of a toxic, oligomeric segment of SOD1 linked to amyotrophic later al sclerosis (ALS). Alexander et al., Validation of the new consensus criteria for the diagnosis o f corticobasal degeneration J neurol Neurosurg Psychiatry 2014: 85: 923-927 Gil D. Rabinovici and Bruce L. Miller CNS Drugs. 2010 May 1; 24(5): 375-398. F rontotemporal Lobar Degeneration: Epidemiology, Pathophysiology, Diagnosis and M anagement Guo Q et al., Cell. 2018 Feb 8;172(4):696-705. In Situ Structure of Neuronal C 9orf72 Poly-GA Aggregates Reveals Proteasome Recruitment. Basso, et al., Mutant Copper-Zinc Superoxide Dismutase (SOD1) Induces Protein Secretion Pathway Alterations and Exosome Release in Astrocytes IMPLICATIONS FOR DISEASE SPREADING AND MOTOR NEURON PATHOLOGY IN AMYOTROPHIC LATERAL SCLEROSIS J BC; 2013 Vol 288 No 22 pp 15699 - 15711 Hinz et al ,. J Biol Chem. 2012 Jan 13;287(3):2068-78. Polyglutamine expansion alters the dynamics and molecular architecture of aggregates in dentatorubropal lidoluysian atrophy. Ruggeri et al., Nat Commun. 2015 Jul 28;6:7831. Infrared nanospectroscopy char acterization of oligomeric and fibrillar aggregates during amyloid formation.
Claims
1. 1. An in vitro method for identifying or monitoring an alpha synucleinopathy in a subject, comprising: a) assessing the amount of at least one ceramide species selected from the group consisting of Cer 32:1, Cer 33:1, Cer 34:1, Cer 34:2, Cer 37:1, Cer 38:1, Cer 38:2, Cer 39:1, Cer 39:2, Cer 40:1, Cer 40:2, Cer 41:1, Cer 41:2, Cer 40:1(OH), and Cer 40:2(OH) in a sample of extracellular vesicles from the subject; b) comparing said estimated amount of said at least one ceramide species to a reference value for said at least one ceramide species; wherein an estimated amount of the at least one ceramide species greater than the reference value for the at least one ceramide species is indicative of an alpha synucleinopathy.
2. 1. An in vitro method for determining a subject's risk of developing an alpha synucleinopathy, comprising: a) assessing the amount of at least one ceramide species selected from the group consisting of Cer 32:1, Cer 33:1, Cer 34:1, Cer 34:2, Cer 37:1, Cer 38:1, Cer 38:2, Cer 39:1, Cer 39:2, Cer 40:1, Cer 40:2, Cer 41:1, Cer 41:2, Cer 40:1(OH), and Cer 40:2(OH) in a sample of extracellular vesicles from the subject; b) comparing said estimated amount of said at least one ceramide species to a reference value for said at least one ceramide species; wherein an assessed amount of the at least one ceramide species greater than the reference value for the at least one ceramide species indicates that the subject is at increased risk for developing an alpha synucleinopathy.
3. 1. An in vitro method for assessing the amount of at least one ceramide species selected from the group consisting of Cer 32:1, Cer 33:1, Cer 34:1, Cer 34:2, Cer37:1, Cer 38:1, Cer 38:2, Cer 39:1, Cer 39:2, Cer 40:1, Cer 40:2, Cer 41:1, Cer 41:2, Cer 40:1(OH), and Cer 40:2(OH) in a subject suspected of having an alpha synucleinopathy or at high risk of developing an alpha synucleinopathy, comprising: (a) providing an extracellular vesicle sample from the subject; (b) Cer 32:1, Cer 33:1, Cer 34:1, Cer 34:2, Cer 37:1, Cer 38:1, Cer 38:2, Cer 39:1, Cer 39:2, Cer 40:1, Cer 40:2, Cer assessing the amount of at least one ceramide species selected from the group consisting of Cer 41:1, Cer 41:2, Cer 40:1(OH), and Cer 40:2(OH); A method comprising:
4. 1. An in vitro method for selecting a treatment for a subject with a disease, comprising: a) assessing the amount of at least one ceramide species selected from the group consisting of Cer 32:1, Cer 33:1, Cer 34:1, Cer 34:2, Cer 37:1, Cer 38:1, Cer 38:2, Cer 39:1, Cer 39:2, Cer 40:1, Cer 40:2, Cer 41:1, Cer 41:2, Cer 40:1(OH), and Cer 40:2(OH) in a sample of extracellular vesicles from the subject; b) comparing said estimated amount of said at least one ceramide species to a reference value for said at least one ceramide species; wherein an assessed amount of the at least one ceramide species greater than the reference value for the at least one ceramide species indicates that the subject will benefit from a treatment for an alpha synucleinopathy.
5. The method of any one of claims 1 to 4, wherein the alpha synucleinopathy is selected from the group consisting of Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.
6. The method of any one of claims 1 to 5, wherein the subject is a human.
7. The method of any one of claims 1 to 6, wherein the subject is suffering from or suspected of suffering from an alpha synucleinopathy.
8. The method of claim 7, wherein the subject is suffering from an alpha synucleinopathy.
9. 9. The method of claim 8, wherein the subject is suffering from early stage alpha synucleinopathy.
10. The method of any one of claims 1 to 9, wherein the extracellular vesicle sample is obtained from a biological sample selected from CSF, blood, brain tissue homogenate, urine, saliva, or a combination thereof.
11. 11. The method of claim 10, wherein the blood sample is selected from the group consisting of plasma, serum, platelets, and buffy coat.
12. The method of claim 10 or 11, wherein the extracellular vesicle sample is obtained using size exclusion chromatography.
13. The method further comprises: i) providing a biological sample from said subject; ii) obtaining an extracellular vesicle sample from the biological sample using size exclusion chromatography; The method of claim 12, comprising:
14. 5. The method of claim 1, 2 or 4, wherein the reference value is obtained from a control sample or is a predetermined reference value.
15. Use of at least one extracellular vesicle ceramide species selected from the group consisting of Cer 32:1, Cer 33:1, Cer 34:1, Cer 34:2, Cer37:1, Cer 38:1, Cer 38:2, Cer 39:1, Cer 39:2, Cer 40:1, Cer 40:2, Cer 41:1, Cer 41:2, Cer 40:1(OH), and Cer 40:2(OH) for identifying or monitoring alpha synucleinopathy in a subject, or for determining the risk of developing alpha synucleinopathy in a subject.
Citation Information
Patent Citations
Exosome-associated microRNAs as diagnostic markers
JP2010534480A
Methods for detecting disease or condition
JP2015522260A
Predictive value of combined genetic enzymatic and lipidomic data in disease risk for lewy body disease
US20180051337A1
Biomarkers of proteopathies and uses thereof
WO2017165766A2
